document incorporate reference portion abbvie inc proxy statement incorporate reference iii proxy statement file march item business separation abbott laboratories january abbvie independent company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott shareholder abbott shareholder record close business december record date receive share abbvie common stock abbott common share hold record date abbvie incorporate delaware april comprise abbott researchbase pharmaceutical business abbvie registration statement form declare effective securities exchange commission december abbvie common stock begin trade regular way ticker symbol abbv new york stock exchange january overview abbvie global researchbase biopharmaceutical company abbvie develop market advanced therapy address world complex disease abbvie product treat rheumatoid arthritis psoriasis crohn disease hiv cystic fibrosis complication low testosterone thyroid disease parkinson disease ulcerative colitis complication associate chronic kidney disease indication abbvie pipeline promise new medicine include compound indication phase phase iii development important medical specialty immunology renal care hepatitis woman health oncology neuroscience include multiple sclerosis alzheimer disease acquisition pharmaceutical business solvay pharmaceutical facet biotech corporation add new product abbvie portfolio include right androgel creon enhance abbvie early midstage investigational pipeline add investigational biologic multiple sclerosis compound complement abbvie oncology program acquisition discuss fully note acquisition collaboration arrangement note combine financial statement segment abbvie operate business segmentpharmaceutical product incorporate reference note entitle segment geographic area information note combine financial statement include item financial statement supplementary data sale information relate humira include financial review product abbvie portfolio proprietary product include broad line adult pediatric pharmaceutical text report term abbvie refers abbvie inc delaware corporation abbvie inc consolidate subsidiary context require humira humira biologic therapy administer subcutaneous injection approve treat follow autoimmune disease united states canada mexico collectively north america european union condition principal market rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylose spondylitis north america european union crohn disease moderate severe north america european union plaque psoriasis moderate severe north america european union juvenile idiopathic arthritis north america european union ulcerative colitis moderate severe united states european union axial spondyloarthritis european union pediatric crohn disease severe european union humira approve market include japan brazil australia humira introduce market january worldwide sale grow approximately billion compare billion billion humira account approximately percent abbvie total sale united states composition matter compound patent cover adalimumab expect expire december equivalent european union patent expect expire majority country april abbvie continue dedicate substantial research development effort expand indication humira include field rheumatology peripheral spondyloarthritis axial spondyloarthritis pediatric enthesitis relate arthritis gastroenterology pediatric crohn disease pediatric ulcerative colitis dermatology pediatric psoriasis hidradenitis suppurativa ophthalmology uveitis phase iii trial ongoing preparation regulatory application uveitis united states european union peripheral axial spondyloarthritis united states peripheral spondyloarthritis european union hidradenitis suppurativa united states european union metabolicshormone product metabolic hormone product target number condition include exocrine pancreatic insufficiency testosterone deficiency hypothyroidism generate combine sale billion product include synthroid synthroid treatment hypothyroidism abbvie sale synthroid total million androgel androgel daily testosterone replacement therapy available strength percent percent abbvie sale androgel total billion creon creon pancreatic enzyme therapy exocrine pancreatic insufficiency condition occur patient cystic fibrosis chronic pancreatitis condition abbvie sale creon total million abbvie right sell synthroid androgel creon united states virology product abbvie virology product include product treatment hiv infection kaletra norvir worldwide sale product billion kaletra kaletra market aluvia emerge market prescription antihiv medicine contain protease inhibitor lopinavir ritonavir kaletra antihiv medication increase chance treatment response people hiv abbvie sale kaletra total billion norvir norvir ritonavir protease inhibitor indicate combination antiretroviral agent treatment hiv infection abbvie sale norvir total million endocrinology product lupron market lucrin lupron depot product palliative treatment advance prostate cancer treatment endometriosis central precocious puberty preoperative treatment patient anemia cause uterine fibroid lupron approve daily subcutaneous injection onemonth threemonth fourmonth sixmonth intramuscular injection lupron generate sale approximately million select market worldwide dyslipidemia product abbvie dyslipidemia product address range metabolic condition characterize high cholesterol andor high triglyceride product generate sale billion primarily market primary care physician include tricor trilipix tricor trilipix fibric acid derivative indicate adjunct diet reduce total cholesterol ldl cholesterol triglyceride level key contributor cardiovascular disease increase hdl cholesterol level abbvie right sell tricor trilipix united states abbvie combine sale tricor trilipix total billion niaspan niaspan extend release form niacin indicate adjunct diet reduce total cholesterol ldl cholesterol triglyceride level increase hdl cholesterol level abbvie right sell niaspan united states abbvie sale niaspan total million product abbvie product include follow synagis synagis product market abbvie outside united states protect atrisk infant severe respiratory disease respiratory syncytial virus rsv abbvie sale synagis total million anesthesia product sevoflurane sell trademark ultane sevorane anesthesia product abbvie sell worldwide human use abbvie sale sevoflurane total million duodopa duopa duodopa levodopacarbidopa intestinal gel lcig market outside united states treat advanced parkinson disease abbvie sale duodopa total million lcig therapy complete phase iii development united states duopa abbvie pursue regulatory approval united states zemplar zemplar product sell worldwide prevention treatment secondary hyperparathyroidism associate stage chronic kidney disease ckd abbvie sale zemplar total million research development activity abbvie numerous compound clinical development include potential treatment highly prevalent condition past year abbvie double number compound pipeline mix internal development external collaboration effort abbvie ability discover develop new compound enhance company use integrate discovery development project team include chemist biologist physician pharmacologist work compound team research development process generally begin discovery research focus identification molecule desire effect give disease preclinical testing identify compound prove successful compound move clinical development generally include follow phase phase iinvolve human test small number healthy volunteer patient assess safety tolerability potential dosing phase iitest molecule efficacy disease relatively small group patient phase iiitest molecule demonstrate favorable result early phase significantly large patient population demonstrate efficacy safety base regulatory criterion clinical trial development phase provide datum require prepare submit new drug application nda biological license application bla submission regulatory approval food drug administration fda similar government agency outside specific requirement scope clinical trial obtain regulatory approval vary different country geographic region research development process discovery new drug launch typically take year long significant uncertainty inherent research development new pharmaceutical product guarantee molecule receive regulatory approval require launch new drug indication addition development new product new formulation research development project include phase trial call postmarkete study project clinical trial design conduct collect additional datum parameter benefit risk approve drug abbvie spend approximately billion billion billion research discover develop new product indication process improve exist product process expense consist primarily collaboration fee expense salary relate expense personnel license fee consult payment contract research manufacturing cost laboratory equipment facility intellectual property protection regulatory exclusivity generally approval product development entitle exclusivity applicable intellectual property regulatory regime abbvie seek patent protection available significant market andor country product development united states expiration date patent file june year filing date give patent relate pharmaceutical product obtain early development process give time need complete clinical trial development activity require regulatory approval length time product launch patent expiration significantly year drug price competition patent term restoration act commonly know hatchwaxman act permit patent holder seek patent extension commonly call patent term restoration patent product process make product regulate federal food drug cosmetic act length patent extension roughly base percent period time file investigational new drug application compound submission nda compound plus percent time period nda submission regulatory approval extension exceed year patent term remain regulatory approval exceed year pharmaceutical product entitle form legal regulatory exclusivity approval scope length requirement exclusivitie vary united states jurisdictions united states fda approve product contain previously approve active ingredient product typically entitle year market exclusivity product entitle year market exclusivity approval base fda reliance new clinical study submit nda applicant nda applicant study product use child fda grant pediatric exclusivity extend day long exist exclusivity patent regulatory relate product product treat condition afflict relatively small population reasonable expectation research development cost recover fda designate pharmaceutical orphan drug grant seven year market exclusivity applicable law regulation dictate market exclusivity product entitle approval particular country certain instance regulatory exclusivity protect product patent protection long available period time excess patent protection possible estimate product development total period exclusivity entitle regulatory approval obtain give length time require complete clinical development pharmaceutical product minimum maximum period exclusivity achieve individual case expect exceed year respectively estimate consider factor difficulty recreate manufacturing process particular product proprietary knowledge delay introduction generic followon product expiration applicable patent regulatory exclusivity period biologics humira entitle exclusivity biologic price competition innovation act pass march title vii patient protection affordable care act law provide pathway approval biosimilar follow expiration year exclusivity innovator biologic potential additional dayextension term conduct pediatric study law include extensive process innovator biologic biosimilar manufacturer litigate patent infringement validity enforceability prior approval biosimilar european union create pathway approval biosimilar publish guideline approval certain biosimilar product complex nature biologic biosimilar product lead great regulatory scrutiny rigorous requirement approval followon biosimilar product smallmolecule generic pharmaceutical product reduce effect biosimilar sale innovator biologic compare sale erosion cause generic version small molecule pharmaceutical product abbvie own license right substantial number patent patent application principal trademark product cover discuss description abbvie product abbvie license own patent portfolio thousand patent family include united states patent application andor issue patent contain nonunite state counterpart patent application patent application include patent expire period aggregate believe material importance operation abbvie business abbvie believe single patent license trademark relate group patent license trademark relate adalimumab sell trademark humira material relation company business united states composition matter compound patent cover adalimumab expect expire december equivalent european union patent expect expire majority country april addition follow patent license trademark significant relate lopinavirritonavir sell trademark kaletra aluvia relate fibric acid derivative sell trademark tricor trilipix relate niacin sell trademark niaspan simcor relate testosterone sell trademark androgel united states composition matter patent cover lopinavir expect expire principal united states noncomposition matter patent cover lopinavirritonavir expect expire principal united states noncomposition matter patent cover fibric acid derivative product expect expire principal united states noncomposition matter patent cover niacin product expect expire principal noncomposition matter patent cover androgel expect expire percent formulation pediatric exclusivity percent formulation agreement affect exclusivity discuss item management discussion analysis financial condition result operationsresult operation abbvie rely circumstance trade secret protect technology trade secret difficult protect abbvie seek protect technology product candidate confidentiality agreement employee consultant advisor contractor collaborator agreement breached abbvie adequate remedy breach addition abbvie trade secret know independently discover competitor extent abbvie employee consultant advisor contractor collaborator use intellectual property own work company dispute arise right relate result knowhow invention sale marketing distribution capability abbvie product sell country abbvie utilize combination dedicate commercial resource regional commercial resource distributorship market sell distribute product worldwide united states abbvie distribute pharmaceutical product principally independent wholesale distributor sale directly pharmacie wholesale distributor account substantially abbvie sale united states sales mckesson corporation cardinal health inc amerisourcebergen corporation account percent percent percent respectively abbvie gross sale united states wholesaler purchase product abbvie standard term condition sale abbvie direct primary marketing effort secure prescription recommendation brand product physician key opinion leader health care provider manage care provider example health maintenance organization pharmacy benefit manager hospital state federal government agency example united states department veterans affairs united states department defense important customer abbvie market directly consumer company product sell pursuant prescription united states outside united states abbvie focus marketing effort key opinion leader payor physicians country regulatory body abbvie provide patient support program closely relate product abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse outside united states sale directly customer distributor depend market serve approximately percent sale outside united states wholesaler distributor wholesaler distributor outside united states account percent abbvie sale certain product comarkete copromote company abbvie single customer customer lose material adverse effect company business material portion abbvie business subject renegotiation profit termination contract election government party agreement abbvie agreement party process development analytical service manufacture certain product abbvie procure certain product service limit number supplier case single supply source example filling package humira syrinx sell outside united states puerto rico perform single supplier different facility abbvie currently believe agreement material abbvie business substantially dependent abbvie maintain significant inventory humira syrinx reduce risk supply disruption await regulatory approval syringefille packaging facility united states supply syrinx outside united states puerto rico facility approve provide product united states puerto rico addition abbvie agreement party active pharmaceutical ingredient product manufacturing formulation development service fill finish packaging service distribution logistic service certain product abbvie believe manufacturingrelate agreement material abbvie business substantially dependent individual agreement case abbvie maintain alternate supply relationship utilize undue disruption manufacturing process party fails perform contractual obligation abbvie maintain sufficient inventory product minimize impact supply disruption abbvie collaboration agreement discuss note acquisition collaboration arrangement note combine financial statement certain agreement abbott describe item certain relationship relate transaction director independence source availability raw material abbvie purchase ordinary course business raw material supply essential operation numerous supplier world include united states recent significant availability problem supply shortage order order generally fill current basis order backlog material abbvie business environmental matter abbvie believe operation comply material respect applicable law regulation concern environmental protection regulation federal state environmental law impose stringent limitation emission discharge environment manufacturing operation abbvie capital operating expenditure pollution control approximately million million respectively capital operating expenditure pollution control estimate approximately million million respectively abbott identify potentially responsible party investigation andor remediation location united states include puerto rico comprehensive environmental response compensation liability act commonly know superfund location transfer abbvie connection separation distribution abbvie party investigation remediations abbott engage remediation site transfer abbvie connection separation distribution cooperation environmental protection agency similar agency feasible predict certainty final cost relate investigation remediation activity abbvie believe cost expenditure maintain compliance applicable law regulation concern environmental protection material adverse effect company financial position cash flow result operation competition market abbvie product highly competitive abbvie compete researchbase pharmaceutical biotechnology company discover manufacture market sell proprietary pharmaceutical product biologic example humira compete number antitnf product approve number disease state abbvie virology product compete protease inhibitor antihiv treatments abbvie dyslipidemia product face competition fibrate statin search technological innovation pharmaceutical product significant aspect competition introduction new product competitor change medical practice procedure result product obsolescence price competitive factor addition substitution generic pharmaceutical product brand pharmaceutical product create competitive pressure abbvie product patent protection biosimilar competition abbvie biologic product affect approval followon biologic know biosimilar biologic add major therapeutic option treatment disease include therapy unavailable inadequate advent biologic raise complex regulatory issue significant pharmacoeconomic concern cost develop produce biologic therapy typically dramatically high conventional small molecule medication expensive biologic medication ongoing treatment chronic disease rheumatoid arthritis inflammatory bowel disease treatment previously untreatable cancer significant investment biologics infrastructure manufacture necessary produce biologic product significant investment market distribution sale organization activity limit number biosimilar competitor united states fda regulate biologics federal food drug cosmetic act public health service act implement regulation enactment federal health care reform legislation march mean provide pathway approval biosimilar public health service act recent regulatory guidance suggest approval process biosimilar far extensive approval process generic followon version small molecule product order ensure safety efficacy biosimilar highly similar original biologic humira ultimate approval fda dependent factor include show biosimilar highly similar original product clinically meaningful difference original product term safety purity potency type datum ordinarily require application similarity include analytical datum study demonstrate chemical similarity animal study include toxicity study clinical study applicable regulation require biosimilar indication original biologic involve mechanism action manufacturing facility meet standard necessary assure biosimilar safe pure potent furthermore new law provide biosimilar product deem interchangeable substitute original biologic product intervention health care provider prescribe original biologic product prove biosimilar product interchangeable applicant demonstrate product expect produce clinical result original biologic product give patient product administer patient safety risk potential diminished efficacy alternating switching use interchangeable biosimilar biologic product original biologic product great risk original biologic product switch new law beginning interpret implement fda result ultimate impact implementation mean likely subject substantial uncertainty year come european union pathway approval biosimilar exist product come market date mixed impact market share incumbent product significant variation product competitive product number competitive biologic brand product approve humira introduce gain modest share worldwide market addition jak inhibitor new class orally administer class product recently approve use rheumatoid arthritis regulatory review europe abbvie continue face competitive pressure biologic orally administer product regulationdiscovery clinical development united states secure approval market new pharmaceutical product united states require substantial effort financial resource take year complete applicant complete preclinical test obtain fda approval commence clinical trial clinical trial intend establish safety efficacy pharmaceutical product typically conduct sequential phase phase overlap combine require clinical testing successful result submit fda form nda biologic listing application bla request approval market product indication fda review nda bla determine product safe effective intended use manufacturing compliant current good manufacturing practice cgmp nda bla receive approval applicant comply postapproval requirement example holder approval report adverse reaction provide update safety efficacy information comply requirement concern advertise promotional labeling quality control manufacturing procedure continue conform cgmp approval fda periodically inspect manufacture facility assess compliance cgmp impose extensive procedural substantive record keeping requirement addition condition approval fda require postmarkete testing surveillance assess monitor product safety efficacy commercialization postapproval regulatory obligation cost comply obligation expand future outside united states abbvie subject similar regulation outside united states abbvie obtain approval clinical trial application product applicable regulatory authority commence clinical trial marketing product approval requirement process vary time require obtain approval long shorter require fda approval example abbvie submit marketing authorization european union centralize decentralize procedure centralize procedure mandatory approval biotechnology product pharmaceutical product provide single marketing authorization valid european union member state centralized procedure single marketing authorization application submit european medicine agency agency evaluate application make recommendation european commission make final determination approve application decentralize procedure provide mutual recognition national approval decision available product subject centralized procedure japan application approval new product pharmaceutical medical device agency pmda bridge study demonstrate foreign clinical datum apply japanese patient require complete comprehensive review pmda report ministry health labour welfare approve deny application regulatory process emerge market continue evolve emerge market include asia generally require regulatory approval obtain large develop market united states country begin complete regulatory review process country require local clinical study conduct order obtain regulatory approval country requirement govern conduct clinical trial product licensing vary addition postapproval regulatory obligation adverse event report cgmp compliance generally apply vary country example marketing authorization grant periodic safety report submit pharmacovigilance measure implement regulationcommercialization distribution manufacturing manufacture marketing sale promotion distribution abbvie product subject comprehensive government regulation government regulation national regional federal state local agency united states country address matter inspection control research laboratory procedure clinical investigation product approval manufacturing labeling packaging marketing promotion pricing reimbursement sampling distribution quality control postmarkete surveillance record keeping storage disposal practice abbvie operation affect trade regulation country limit import raw material finish product law regulation seek prevent corruption bribery marketplace include united states foreign corrupt practice act united kingdom bribery act provide guidance corporate interaction government official require safeguard protection personal datum addition abbvie subject law regulation pertain health care fraud abuse include state federal antikickback false claim law united states prescription drug manufacturer abbvie subject taxis application product user establishment fee compliance law regulation costly materially affect abbvie business effect health care regulation substantially increase time difficulty cost incur obtain maintain approval market newly develop exist product abbvie expect compliance regulation continue require significant technical expertise capital investment ensure compliance failure comply delay release new product result regulatory enforcement action seizure recall product suspension revocation authority necessary product production sale civil criminal sanction include fine penalty addition regulatory initiative abbvie business affect ongoing study utilization safety efficacy outcomes health care product component regularly conduct industry participant government agency study question utilization safety efficacy previously market product case study result future result discontinuance limitation marketing product domestically worldwide rise claim damage person believe injure result use access human health care product continue subject investigation action governmental agency legislative body private organization united states country major focus cost containment effort reduce health care cost private sector notably health care payor provider institute cost reduction containment measure abbvie expect insurer provider continue attempt reduce cost health care product outside united states country control price health care product directly indirectly reimbursement payment pricing coverage limitation compulsory license budgetary pressure united states country heighten scope severity pricing pressure abbvie product foreseeable future united states specifically federal law require pharmaceutical manufacturer pay certain statutorilyprescribe rebate state medicaid programs prescription drug reimburse state medicaid plan effort state seek additional rebate affect abbvie business similarly veteran health care act prerequisite participation medicaid federal health care program require manufacturer extend additional discount pharmaceutical product federal agency include department veterans affairs department defense public health service entity institution addition recent legislative change require similarly discount price offer tricare program beneficiary act establish drug discount program require pharmaceutical manufacturer provide product reduce price designate health care entity facilities united states states generic substitution legislation require permit dispense pharmacist substitute different manufacturer generic version pharmaceutical product prescribe addition federal government follows diagnosisrelate group drg payment system certain institutional service provide medicare medicaid implement prospective payment system pps service deliver hospital outpatient nursing home home health setting drg pps entitle health care facility fix reimbursement base diagnosis andor procedure actual cost incur patient treatment increase incentive facility limit control expenditure health care product medicare reimburse drug base average sale price asp plus certain percentage account physician administration cost recently reduce hospital outpatient set end stage renal disease treatment cover bundle payment likewise create incentive provider demand low pharmaceutical price medicare enter contract private plan negotiate price patientadministere medicine deliver march congress enact patient protection affordable care act health care education reconciliation act affordable care act affordable care act abbvie pay fee relate pharmaceutical sale government program abbvie begin provide discount percent brand prescription drug sell patient fall medicare coverage gap donut hole affordable care act include provision know physician payment sunshine act require manufacturers drug biologics cover medicare medicaid start record transfer value physician teach hospital report datum beginning center medicare medicaid services subsequent public disclosure similar reporting requirement enact state level united states increase number country worldwide adopt consider similar law require disclosure interaction health care professional failure report appropriate datum result civil criminal fine andor penalty abbvie expect debate continue government level worldwide marketing availability method delivery payment health care product service abbvie believe future legislation regulation market serve affect access health care product service increase rebate reduce price rate price increase health care product service change health care delivery system create new fee obligation pharmaceutical industry require additional reporting disclosure possible predict extent abbvie health care industry general affect matter discuss abbvie subject corporate integrity agreement cia enter abbott require enhancement abbvie compliance program contain report obligation include disclosure financial payment doctor abbvie fail comply cia office inspector general department health human service impose monetary penalty exclude abbvie federal health care program include medicare medicaid european union adopt directive legislation govern label advertising distribution supply pharmacovigilance marketing pharmaceutical product legislation provide mandatory standard permit member states supplement standard additional regulation european government regulate pharmaceutical product price control national health care system fund large cost product consumer result patient unlikely use pharmaceutical product reimburse government european country government regulate price new product launch subsequent launch direct price control reference pricing recent year country impose new additional cost containment measure pharmaceutical product difference national pricing regime create price differential lead significant parallel trade pharmaceutical product government promote generic substitution mandate permit pharmacist substitute different manufacturer generic version pharmaceutical product prescribe permit mandate health care professional prescribe generic version certain circumstance addition government use reimbursement list limit pharmaceutical product eligible reimbursement national health care systems japan japan national health insurance system maintain drug price list specify pharmaceutical product eligible reimbursement ministry health labour welfare set price product list government generally introduce price cut round year mandate price decrease specific product new product judge innovative useful indicate pediatric use target orphan small population disease eligible pricing premium government promote use generic available emerge market emerge market step reduce pharmaceutical product price case direct price control promotion generic alternative brand pharmaceutical abbvie market product worldwide certain product local nature variation product line meet local regulatory requirement certain additional risk inherent conduct business outside united states include price currency exchange control change currency exchange rate limitation participation local enterprise expropriation nationalization governmental action employee abbvie employ approximately person january outside united states abbvie employee represent union work council abbvie believe good relation employee internet information copy abbvie annual report quarterly report form current report form amendment report file furnish pursuant section security exchange act available free charge abbvie investor relation website wwwabbvieinvestorcom soon reasonably practicable abbvie electronically file material furnish securities exchange commission abbvie corporate governance guideline outline directorship qualification code business conduct charters abbvie audit committee compensation committee nomination governance committee public policy committee available abbvie investor relation website wwwabbvieinvestorcom item risk factor carefully consider follow risk information evaluate abbvie abbvie common stock follow risk materially adversely affect abbvie result operation financial condition risk factor generally separate group risk relate abbvie business risk relate abbvie recent separation abbott risk relate abbvie common stock base information currently know abbvie believe follow information identify significant risk factor affect category risk risk uncertainty abbvie face limit set forth risk factor describe order importance probability occurrence additional risk uncertainty presently know abbvie abbvie currently believe immaterial adversely affect business addition past financial performance reliable indicator future performance historical trend anticipate result trend future period follow risk uncertainty develop actual event event material adverse effect abbvie business financial condition result operation case trading price abbvie common stock decline risk relate abbvie business expiration loss patent protection license adversely affect abbvie future revenue operate income abbvie rely patent trademark intellectual property protection discovery development manufacturing sale product particular patent protection aggregate important abbvie marketing pharmaceutical product united states major market outside united states patent cover abbvie product normally provide market exclusivity important profitability abbvie product patent certain product expire abbvie face competition lower price generic product expiration loss patent protection product typically follow promptly substitute significantly reduce sale product short time abbvie competitive position compromise generic material adverse effect abbvie business result operation addition proposal emerge time time legislation encourage early rapid approval generic drug proposal enact law worsen effect generic competition abbvie principal patent trademark describe great detail item businessintellectual property protection regulatory exclusivity item management discussion analysis financial condition result operationsresult operation litigation patent describe item legal proceeding composition matter patent humira abbvie large selling product worldwide sale approximately billion expect expire december equivalent european union patent expect expire majority country april humira biologic biologic readily substitute uncertain impact loss patent protection sale humira abbvie major product lose patent protection early expect adversely affect abbvie future revenue operate income party government authority challenge seek invalidate circumvent abbvie patent patent application example manufacturer generic pharmaceutical product file continue file abbreviate new drug application andas united states food drug administration fda seek market generic form abbvie product prior expiration relevant patent own license abbvie assert patent invalid unenforceable andor infringe example certain company file anda seek approval market generic version fenofibric acid capsule trilipix niacin extend release tablet niaspan company assert abbvie patent cover product invalid unenforceable andor infringe respective product abbvie enter settlement agreement resolve substantially challenge description material pende challenge refer item legal proceeding challenge abbvie intellectual property come business government challenge intellectual property right example court decision potential legislation relate patent legislation biosimilar regulatory initiative result erosion intellectual property protection addition certain government outside united states indicate compulsory license patent seek domestic policy basis national emergency hivaid trigger compulsory license diminish eliminate sale profit jurisdiction negatively affect abbvie result operation abbvie normally respond challenge vigorously defend patent include file patent infringement lawsuit patent litigation challenge abbvie patent costly unpredictable deprive abbvie market exclusivity patent product extent abbvie intellectual property successfully challenge circumvent extent intellectual property allow abbvie compete effectively abbvie business suffer extent country enforce abbvie intellectual property right require compulsory licensing abbvie intellectual property abbvie future revenue operating income reduce party intellectual property prevent abbvie selling product material adverse effect abbvie future profitability financial condition party claim abbvie product infringe intellectual property resolve intellectual property infringement claim costly time consuming require abbvie enter license agreement abbvie guarantee able obtain license agreement commercially reasonable term successful claim patent intellectual property infringement subject abbvie significant damage injunction prevent manufacture sale use affect abbvie product product event material adverse effect abbvie profitability financial condition significant event adversely affect humira revenue material negative impact abbvie result operation cash flow humira generate approximately percent abbvie sale significant event adversely affect humira revenue material adverse impact abbvie operation cash flow event include loss patent protection humira approval biosimilar humira discovery previously unknown effect impair efficacy increase competition introduction new effective expensive treatment discontinuation removal market humira reason abbvie research development effort succeed develop marketing commercially successful product technology cause revenue profitability decline remain competitive abbvie continue launch new product new indication andor brand extension exist product launch generate revenue sufficient cover substantial research development cost replace sale profitable product lose displace compete product therapy failure material adverse effect abbvie revenue profitability accordingly abbvie commit substantial effort fund resource research development ongoing substantial expenditure assurance effort commercially successful example abbvie discontinue development abt phase development treatment hematologic malignancie high rate failure biopharmaceutical industry inherent research development new product failure occur point research development process include significant fund invest product appear promise development fail reach market numerous reason include failure demonstrate effectiveness safety concern superior safety efficacy compete therapy failure achieve positive clinical preclinical outcome current standard care inability obtain necessary regulatory approval delay approval new product new indication limited scope approve use excessive cost manufacture failure obtain maintain intellectual property right infringement intellectual property right decision research study early development process pharmaceutical product candidate affect marketing strategy candidate receive approval detailed study demonstrate additional benefit help marketing consume time resource delay submit pharmaceutical product candidate approval abbvie guarantee proper balance speed testing respect pharmaceutical product candidate decision area adversely affect abbvie future result abbvie successfully develop market new product enhancement exist product quickly render obsolete change clinical preference change industry standard competitor innovation abbvie innovation accept quickly marketplace exist clinical practice uncertainty thirdparty reimbursement abbvie state certainty product development launch able develop license acquire compound product product commercially successful failure launch successful new product new indication exist product cause abbvie product obsolete cause abbvie revenue operate result suffer portion abbvie nearterm pharmaceutical pipeline rely collaboration party adversely affect development sale product abbvie depend alliance pharmaceutical biotechnology company portion product nearterm pharmaceutical pipeline example abbvie collaborate biogen idec develop treatment relapse remit form collaborate bristolmyer squibb treatment multiple myeloma biotest compound rheumatoid arthritis psoriasis failure party meet contractual regulatory obligation abbvie disruption relationship abbvie party adverse effect abbvie pharmaceutical pipeline business addition abbvie collaborative relationship research development extend year rise dispute relative right obligation revenue abbvie collaboration partner include ownership intellectual property associate right obligation result loss intellectual property right protection delay development sale potential pharmaceutical product lead lengthy expensive litigation arbitration biologic carry unique risk uncertainty negative impact future result operation successful discovery development manufacturing sale biologic long expensive uncertain process unique risk uncertainty biologic example access supply necessary biological material cell line limit governmental regulation restrict access regulate transport use material addition development manufacturing sale biologic subject regulation complex extensive regulation applicable pharmaceutical product manufacture biologic especially large quantity complex require use innovative technology manufacturing require facility specifically design validate purpose sophisticated quality assurance quality control procedure biologic frequently costly manufacture production input derive live animal plant material biologic synthetically failure successfully discover develop manufacture sell biologicsincluding humira adversely impact abbvie business result operation new product technological advance abbvie competitor negatively affect abbvie result operation abbvie compete researchbase pharmaceutical biotechnology company discover manufacture market sell proprietary pharmaceutical product biologic example humira compete number antitnf product approve number disease states abbvie virology product compete protease inhibitor antihiv treatments abbvie dyslipidemia product face competition fibrate statin competitor introduce new product develop technological advance compete abbvie product therapeutic area immunology virology renal disease dyslipidemia neuroscience abbvie predict certainty timing impact introduction competitor new product technological advance compete product safer effective effectively market sell low price superior performance feature abbvie product negatively impact abbvie business result operation abbvie biologic product subject competition biosimilar biologics price competition innovation act pass march title vii patient protection affordable care act law create framework approval biosimilar united states allow competitor reference datum biologic product approve europe european commission grant marketing authorization biosimilar pursuant set general product classspecific guideline biosimilar approval issue past year addition company develop biosimilar country compete abbvie biologic product competitor able obtain marketing approval biosimilar reference abbvie biologic product abbvie product subject competition biosimilar attendant competitive pressure consequence expiration successful challenge abbvie applicable patent right trigger competition product assume relevant exclusivity period expire result abbvie face litigation respect validity andor scope patent relate biologic product manufacture abbvie product highly exact complex process abbvie supplier encounter problem manufacture abbvie product abbvie business suffer manufacture abbvie product highly exact complex process strict regulatory requirement problem arise manufacturing variety reason include equipment malfunction failure follow specific protocol procedure problem raw material delay relate construction new facility expansion exist facility include intended support future demand abbvie product change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation inhibit continuous supply manmade natural disaster environmental factor problem arise production batch product batch product discard abbvie experience product shortage incur add expense thing lead increase cost lose revenue damage customer relation time expense spend investigate cause depend cause similar loss respect batch product problem discover product release market recall product liability cost incur abbvie rely single source supply certain product service interruption supply product service adversely affect abbvie business result operation abbvie single source supply certain product service example filling package humira syrinx sell outside united states puerto rico perform single supplier different facility abbvie maintain significant inventory humira syrinx intend reduce risk supply disruption await regulatory approval syringefille packaging facility united states supply syrinx outside united states puerto rico abbvie use number product manufacturing process humira currently source single supplier abbvie believe alternative source product manufacturing process humira currently available failure singlesource supplier fulfill contractual obligation timely manner result regulatory noncompliance physical disruption manufacturing site impair abbvie ability deliver product customer timely competitive basis adversely affect abbvie business result operation find alternative supplier significant time involve significant expense nature service need obtain regulatory approval abbvie guarantee able reach agreement alternative provider regulatory authority approve abbvie use alternative abbvie carry business interruption insurance provide degree protection case failure singlesource supplier significant safety efficacy issue arise abbvie product material adverse effect abbvie revenue financial condition pharmaceutical product receive regulatory approval base datum obtain control clinical trial limit duration follow regulatory approval product long period time patient investigator conduct additional extensive study addition product withdrawal significant safety issue relate pharmaceutical product time obtain regulatory approval increase industrywide health authority rereviewe select product market new safety efficacy issue report new scientific information available include result postmarkete phase trial change government standard safety efficacy labeling abbvie require amend condition use product fda authority base new clinical scientific information require postmarkete study clinical trial label change compliance fda approve risk evaluation mitigation strategy fda exercise authority result delay increase cost product development clinical trial regulatory review increase cost comply additional postapproval regulatory requirement potential restriction market approve product regulatory agency outside united states similar authority new safety datum emerge adverse event report postmarkete study conduct abbvie mandate regulatory agency voluntary source adversely affect sale abbvie product example abbvie voluntarily provide require provide update information product label narrow approve indication reduce product market acceptance safety efficacy issue abbvie product arise sale product halt abbvie regulatory authority safety efficacy issue affect supplier competitor product reduce market acceptance abbvie product new data abbvie product product similar product negatively impact demand abbvie product real perceive safety issue uncertainty efficacy case result product withdrawal furthermore new data information include information product misuse lead government agency professional society practice management group organization involve disease publish guideline recommendation relate use abbvie product use related therapy place restriction sale guideline recommendation lead low sale abbvie product abbvie subject product liability claim lawsuit adversely affect business result operation ordinary course business abbvie subject product liability claim lawsuit allege abbvie product product company promote result result unsafe condition injury patient product liability claim lawsuit safety alert product recall regardless ultimate outcome material adverse effect abbvie business reputation ability attract retain customer consequence include additional cost decrease market share product low income exposure claim product liability loss selfinsure product liability claim material adverse effect abbvie business result operation abbvie subject costcontainment effort pricing pressure cause reduction future revenue operate income costcontainment effort government private organization describe great detail item businessregulationcommercialization distribution manufacturing extent cost containment effort offset great demand increase patient access health care factor abbvie future revenue operating income reduce united states european union country abbvie business experience downward pressure product pricing pressure increase future united states practice manage care group institutional governmental purchaser federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act contribute pricing pressure recently enact change health care system united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result additional pricing pressure numerous major market worldwide government play significant role fund health care service determine pricing reimbursement pharmaceutical product consequently market abbvie subject government decisionmake budgetary action respect product particular governmentmandate price reduction pharmaceutical product european country abbvie anticipate continue pricing pressure europe difference country pricing regulation lead thirdparty crossborder trading abbvie product result reduction future revenue operate income abbvie subject numerous governmental regulation costly comply regulation develop compliant product process abbvie product subject rigorous regulation numerous international supranational federal state authority describe item business regulationdiscovery clinical development process obtain regulatory approval market pharmaceutical product costly time consume approval grant future product additional indication use exist product timely basis delay receipt failure obtain approval future product new indication use result delay realization product revenue reduction revenue substantial additional cost addition abbvie guarantee remain compliant applicable regulatory requirement approval obtain product requirement include thing regulation manufacturing practice product label advertising postmarkete reporting include adverse event report field alert manufacturing quality concern abbvie facility procedure supplier subject ongoing regulation include periodic inspection regulatory authority abbvie incur expense spend time effort ensure compliance complex regulation possible regulatory action event noncompliance include warning letter fine damage injunction civil penalty recall seizures abbvie product criminal prosecution action result substantial modification abbvie business practice operation refund recall seizures abbvie product total partial shutdown production abbvie supplier facility abbvie supplier remedy allege violation inability obtain future approval withdrawal suspension current product market event disrupt abbvie business material adverse effect business result operation law regulation affect government benefit program impose new obligation abbvie require change business practice restrict operation future health care industry subject federal state international law regulation pertain government benefit program reimbursement rebate price reporting regulation health care fraud abuse united states law include antikickback false claim law medicaid rebate statute veterans health care act individual state law relate pricing sale marketing practice violation law punishable criminal andor civil sanction include instance substantial fine imprisonment exclusion participation federal state health care program include medicare medicaid veterans administration health program law regulation broad scope subject evolving interpretation require abbvie incur substantial cost associate compliance alter sale marketing practice addition violation law allegation violation disrupt abbvie business result material adverse effect business result operation change law regulation adversely affect abbvie business describe development manufacture marketing sale promotion distribution abbvie product subject comprehensive government regulation change regulation affect abbvie way example patient protection affordable care act health care education reconciliation act abbvie pay fee relate pharmaceutical sale government program begin record report transfer value physician teach hospital similar reporting requirement enact state level united states european union increase number country worldwide adopt consider similar law future legislation regulation market abbvie serve affect access health care product service increase rebate reduce price rate price increase health care product service change health care delivery system create new fee obligation pharmaceutical industry require additional reporting disclosure legislation regulation adversely affect abbvie business result operation cash flow financial condition prospect abbvie subject increase monetary penalty andor sanction include exclusion federal health care program fail comply term resolution department justice investigation sale marketing activity depakote abbott settle federal state investigation sale marketing activity depakote plead guilty misdemeanor violation food drug cosmetic act fdca agree pay approximately million criminal fine forfeiture approximately million resolve civil claim noncash charge relate investigation previously record discuss item management discussion analysis financial condition result operation plea agreement abbott submit term probation initially set year shorten year obligation plea agreement transfer fully bind abbvie condition probation include certain reporting requirement maintenance certain compliance measure certification abbvie ceo board director condition abbvie violate term probation face additional monetary sanction remedy court deem appropriate october court accept guilty plea impose agreedupon sentence addition abbott enter fiveyear corporate integrity agreement cia office inspector general department health human service oig effective date cia october obligation cia transfer fully bind abbvie cia require enhancement abbvie compliance program fulfillment report monitoring obligation management certification resolution abbvie board director requirement abbvie fail comply cia oig impose monetary penalty exclude abbvie federal health care program include medicare medicaid abbvie abbott subject party claim shareholder lawsuit connection settlement abbvie require indemnify portion abbott cost abbvie compliance obligation resolution department justice investigation sale marketing activity depakote impose additional cost burden abbvie abbott settle federal state investigation sale marketing activity depakote plead guilty misdemeanor violation fdca agree pay criminal fine forfeiture civil damage submit term probation october court accept guilty plea impose agreedupon sentence addition abbott enter fiveyear cia oig effective october obligation plea agreement cia transfer fully bind abbvie compliance requirement settlement impose additional cost burden abbvie include form employee training party review compliance monitoring report obligation management attention international nature abbvie business subject additional business risk cause revenue profitability decline abbvie business subject risk associate business internationally sale outside united states approximately percent abbvie net sale risk associate operation outside united state include fluctuation currency exchange rate change medical reimbursement policy program multiple legal regulatory requirement subject change restrict abbvie ability manufacture market sell product differ local product preference product requirement trade protection measure import export licensing requirement difficulty establish staffing manage operation differ labor regulation potentially negative consequence change interpretation tax law political economic instability include sovereign debt issue price currency exchange control limitation participation local enterprise expropriation nationalization governmental action inflation recession fluctuation interest rate compulsory licensing diminish protection intellectual property potential penalty adverse consequence violation anticorruption antibribery similar law regulation include foreign corrupt practice act bribery act event contemplate risk individually aggregate material adverse effect abbvie revenue profitability deterioration economic position credit quality certain european country negatively affect abbvie result operation financial instability fiscal deficit certain european country include greece italy portugal spain result additional austerity measure reduce cost include health care cost economic condition continue worsen result lengthen time reduce collectability abbvie outstanding trade receivables increase government effort reduce health care spending lead reduction drug price utilization abbvie product ongoing sovereign debt issue country increase abbvie collection risk give significant abbvie receivables country governmental health care system abbvie able realize expect benefit investment emerge market abbvie seek investment key emerge market include brazil china india mexico russia turkey guarantee effort expand sale market succeed emerge market especially vulnerable period financial instability limited resource spend health care abbvie successfully implement emerge market strategy abbvie attract retain qualified personnel require increase reliance thirdparty distributor certain emerge market country currency fluctuate substantially currency devalue abbvie offset devaluation financial performance country adversely affect addition price currency exchange control limitation participation local enterprise expropriation nationalization governmental action affect abbvie business result operation emerge market abbvie acquire business license right technology product form alliance dispose asset cause incur significant expense negatively affect profitability abbvie pursue acquisition technology licensing arrangement strategic alliance dispose asset business strategy abbvie complete transaction timely manner costeffective basis realize expect benefit abbvie successful making acquisition product technology acquire successful require significantly great resource investment originally anticipate abbvie able integrate acquisition successfully exist business incur assume significant debt unknown contingent liability abbvie experience negative effect report result operation acquisition dispositionrelate charge amortization expense relate intangible charge impairment longterm asset effect cause deterioration abbvie credit rating result increase borrowing cost interest expense additionally change abbvie structure operation revenue cost efficiency result major transaction acquisition divestiture merger alliance restructuring strategic initiative result great expect cost long expect complete encounter difficulty include need regulatory approval appropriate abbvie dependent wholesale distributor distribution product united states accordingly result operation adversely affect encounter financial difficulty wholesale distributorsamerisourcebergen corporation cardinal health inc mckesson corporationaccounte substantially abbvie sale united states significant wholesale distributor encounter financial difficulty distributor decrease business abbvie abbvie unable collect amount distributor owe timely basis negatively impact abbvie business result operation change term rebate chargeback programs common pharmaceutical industry material adverse effect abbvie operation rebate relate government program feeforservice medicaid medicaid manage care program arise law regulation abbvie predict additional government initiative contain health care cost factor lead new modify regulatory requirement include high incremental rebate discount rebate discount program arise contractual agreement private payer factor include market factor ability private payer control patient access product provide payer leverage negotiate high additional rebate discount material adverse effect abbvie operation abbvie subject evolve complex tax law result additional liability affect result operation abbvie subject evolve complex tax law jurisdiction operate significant judgment require determine abbvie tax liability abbvie tax return periodically examine tax authority abbott retain risk tax contingency arise operation preseparation abbvie bear risk future tax contingency arise operation postseparation complexity tax contingency ultimate resolution tax matter relate operation postseparation result payment great amount accrue addition abbvie impact change tax law include tax rate change change law relate treatment remittance foreign earning new tax law subsequent interpretation tax law united states jurisdiction abbvie debt obligation adversely affect business ability meet obligation debt abbvie incur intend incur important consequence abbvie investor include require portion abbvie cash flow operation interest payment debt increase abbvie vulnerability general adverse economic industry condition reduce cash flow available fund capital expenditure corporate purpose grow abbvie business limit abbvie flexibility planning react change abbvie business industry extent abbvie incur additional indebtedness risk describe increase addition abbvie cash flow operation sufficient repay outstanding debt abbvie able borrow money sell asset raise fund acceptable term refinance debt term abbvie debt contain covenant restrict financial flexibility number way include thing restriction abbvie ability ability certain abbvie subsidiary incur mortgage respect principal domestic property enter sale leaseback transaction respect principal domestic property restriction abbvie ability merge consolidate entity convey transfer lease abbvie property asset substantially entirety abbvie breach restrictive covenant indebtedness event default occur respect indebtedness abbvie lender indebtedness entitle declare amount owe respect thereof immediately payable challenge commercial credit environment adversely affect abbvie future access capital abbvie ability issue debt enter financing arrangement acceptable term adversely affect material decline demand abbvie product solvency customer supplier significantly unfavorable change economic condition volatility world financial market increase borrowing cost affect abbvie ability access capital market condition adversely affect abbvie ability obtain maintain investment grade credit rating investment abbvie cash balance investment marketable security subject risk cause loss affect liquidity investment abbvie cash currently invest bank deposit money market mutual fund typically hold debt security issue federal government highgrade corporate issuer investment abbvie future investment subject credit liquidity market interest rate risk investment suffer market price decline abbvie recognize earning decline fair value investment cost basis decline judge temporary risk associate abbvie expect cash balance investment portfolio material adverse effect abbvie result operation financial condition abbvie need additional financing future meet capital need opportunistic acquisition financing available favorable term dilutive exist stockholder abbvie need seek additional financing general corporate purpose example need increase investment research development activity need fund acquisition abbvie unable obtain desire additional financing term favorable abbvie lose investment grade credit rating adequate fund available acceptable term abbvie unable fund expansion successfully develop enhance product respond competitive pressure negatively affect abbvie business abbvie raise additional fund issuance equity security stockholder experience dilution ownership interest abbvie raise additional fund issue debt enter credit facility subject limitation operation restrictive covenant failure comply covenant adversely affect abbvie business abbvie depend information technology failure system adversely affect abbvie business abbvie rely sophisticated information technology system operate business system potentially vulnerable malicious intrusion random attack loss datum privacy breakdown abbvie invest protection datum information technology monitor system ongoing basis assurance effort prevent breakdown breaches abbvie information technology system adversely affect abbvie business factor material adverse effect abbvie profitability financial condition factor affect abbvie profitability financial condition include change interpretation law regulation include change accounting standard taxation requirement product marketing application standard environmental law difference fair value measurement asset liability actual value particularly pension retiree health care stock compensation intangible goodwill contingent liability litigation absence record record minimum compare actual change rate inflation include cost raw material commodity supply interest rate market value abbvie equity investment performance investment hold employee benefit trust change creditworthiness counterpartie transact business provide service abbvie employee benefit trust change business economic political condition include war political instability terrorist attack threat future terrorist activity relate military action natural disaster cost availability insurance forego event labor dispute strike slowdown form labor union activity pressure thirdparty interest group risk relate abbvie separation abbott abbvie historical financial information necessarily representative result achieve separate publicly trade company reliable indicator future result historical information abbvie annual report refer abbvie business operate integrated abbott abbvie historical financial information derive consolidated financial statement accounting record abbott accordingly financial information include annual report necessarily reflect financial condition result operation cash flow abbvie achieve separate publicly trade company period present abbvie achieve future primarily result factor describe prior separation abbvie business operate abbott broad corporate organization independent company abbott affiliate perform corporate function abbvie accounting information technology finance abbott currently provide function abbvie describe item certain relationship relate transaction director independence abbvie historical financial result reflect allocation corporate expense abbott function likely expense abbvie incur operate separate publicly trade company abbvie need significant investment replicate outsource provider certain facility system infrastructure personnel abbvie long access result separation abbott initiatives develop abbvie independent ability operate access abbott exist operational administrative infrastructure costly implement abbvie able operate business efficiently comparable cost profitability decline prior separation abbvie able use abbott size purchasing power procure good service share economy scope scale cost employee vendor relationship customer relationship abbvie enter transition agreement abbott arrangement fully capture benefit abbvie previously enjoy result integrate abbott result abbvie pay high charge past service separate independent company abbvie unable obtain good service price term obtain prior separation decrease abbvie overall profitability separate independent company abbvie successful negotiate favorable tax treatment credit governmental entity adverse effect abbvie result operation financial condition generally abbvie work capital requirement capital general corporate purpose include acquisition research development capital expenditure historically satisfied corporatewide cash management policy abbott result separation abbvie need obtain additional financing bank public offering private placement debt equity security strategic relationship arrangement cost capital abbvie business high abbott cost capital prior separation significant change occur abbvie cost structure management financing business operation result operate company separate abbott additional information past financial performance abbvie business basis presentation financial statement abbvie business item management discussion analysis financial condition result operation item financial statement supplementary data abbvie build information technology infrastructure transition datum system abbvie incur substantial additional cost experience temporary business interruption abbvie expect install implement information technology infrastructure support critical business function include accounting reporting manufacturing process control customer service inventory control distribution abbvie incur temporary interruption business operation transition effectively abbott exist transactional operational system datum center transition service support function abbvie replace system abbvie successful implement new system transition datum incur substantially high cost implementation currently anticipate abbvie failure avoid operational interruption implement new system replace abbott information technology service failure implement new system replace abbott service successfully disrupt business adversely affect ability collect receivables customer material adverse effect profitability addition abbvie unable replicate transition certain system ability comply regulatory requirement impaired abbott fail perform transaction agreement execute separation abbvie fail necessary system service place certain transaction agreement expire connection separation abbvie abbott enter separation distribution agreement agreement include transition service agreement tax sharing agreement international commercial operation agreement finish good supply agreement contract manufacturing agreement employee matter agreement special product master agreement information technology agreement transitional trademark license agreement agreement discuss great detail item certain relationship relate transaction director independence certain agreement provide performance service company benefit period time abbvie separation abbott abbvie rely abbott satisfy performance payment obligation agreement abbott unable satisfy obligation agreement include indemnification obligation abbvie incur operational difficulty loss addition abbvie abbott enter longterm arrangement special product master agreement relate certain product right transition service agreement abbott provide abbvie office function service certain market outside united states abbvie establish sufficient office infrastructure conduct operation market arrangement lead dispute abbott abbvie abbvie right certain intellectual property territorial commercialization right allocation cost revenues abbvie product operation outside united states abbvie place systems service abbvie agreement provider service transaction longterm agreement terminate abbvie able operate business effectively profitability decline abbvie process create engage party provide system service replace system service abbott currently provide abbvie successful effectively efficiently implement system service transition datum abbott system abbvie system service expensive efficient system service abbott expect provide transition period abbvie develop implement office function administrative system personnel process market outside united states abbott initially provide function assurance abbvie able implement function effectively disrupt business market potential indemnification liability abbott pursuant separation agreement materially adversely affect abbvie separation agreement abbott provide thing principal corporate transaction require effect separation certain condition separation provision govern relationship abbvie abbott respect result separation description separation agreement item certain relationship relate transaction director independence thing separation agreement provide indemnification obligation design abbvie financially responsible substantially liability exist relate business activity incur prior abbvie separation abbott obligation abbott assume abbvie pursuant separation agreement include relate depakote abbvie require indemnify abbott circumstance set forth separation agreement abbvie subject substantial liability abbvie able engage certain corporate transaction twoyear period follow distribution preserve taxfree treatment abbott separation distribution tax sharing agreement abbvie enter abbott abbvie restrict take action prevent distribution relate transaction taxfree federal income tax purpose tax sharing agreement twoyear period follow distribution abbvie prohibit certain circumstance enter transaction result acquisition percent stock substantially asset merger merge consolidate liquidating issue equity security certain threshold repurchase capital stock cease actively conduct business restriction limit abbvie ability pursue certain strategic transaction transaction believe good interest stockholder increase value business addition tax sharing agreement abbvie require indemnify abbott tax liability result acquisition abbvie stock asset participate facilitate acquisition certain abbvie executive officer director actual potential conflict interest previous continue position abbott position abbott certain executive officer director abbott common share option purchase abbott common share equity award abbvie board director consist majority director independent abbvie executive officer employee abbott cease employee abbott abbvie executive officer director continue financial interest abbott common share addition abbvie director currently serve board director abbott continue ownership abbott common share equity awards service director company create appear create potential conflict interest abbvie abbott pursue corporate opportunity face decision different implication abbvie abbott abbvie achieve expect benefit separation separation adversely affect abbvie business abbvie able achieve strategic financial benefit expect result separation benefit delay occur separation distribution expect provide follow benefit distinct investment identity allow investor evaluate merit performance future prospect abbvie separately abbott efficient allocation capital abbvie iii direct access abbvie capital market abbvie achieve anticipate benefit variety reason include abbvie susceptible market fluctuation adverse event abbott abbvie business diversified abbott business prior separation action require separate abbott abbvie respective business divert management attention planning grow operate abbvie business create disruption abbvie operation case impact abbvie performance future abbvie fail achieve benefit expect result separation benefit delay business financial condition result operation abbvie adversely affect abbvie receive well term unaffiliated party term receive agreement abbott agreements abbvie enter abbott connection separation include transition service agreement tax sharing agreement international commercial operation agreement finish good supply agreement contract manufacturing agreement employee matter agreement special product master agreement information technology agreement transitional trademark license agreement prepare context separation abbvie whollyowne subsidiary abbott accordingly period term agreement prepare abbvie independent board director management team independent abbott result term agreement reflect term resulted negotiation unaffiliate party negotiation abbott unaffiliate party form transaction buyer sale business transaction resulted favorable term unaffiliated party item certain relationship relate transaction director independence risk relate abbvie common stock abbvie stock price fluctuate significantly abbvie predict price share common stock trade market price abbvie common stock fluctuate significantly number factor abbvie control include actual anticipate fluctuation abbvie operating result change earning estimate security analyst abbvie ability meet estimate operate stock price performance comparable company change regulatory legal environment abbvie operate domestic worldwide economic condition addition market price company common stock drop significantly stockholder institute security class action lawsuit company lawsuit abbvie cause incur substantial cost divert time attention management resource abbvie guarantee timing payment dividend common stock abbvie expect pay regular cash dividend time declaration payment future dividend stockholder fall discretion abbvie board director board decision payment dividend depend factor abbvie financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board deem relevant information item market registrant common equity relate stockholder matter issuer purchase equity security abbvie ability pay dividend depend ongoing ability generate cash operation access capital market abbvie guarantee pay dividend future continue pay dividend abbvie commence pay dividend percentage ownership abbvie dilute future future percentage ownership abbvie dilute equity issuance capital market transaction equity awards abbvie grant abbvie director officer employee acquisition purpose abbvie employee option purchase share common stock result conversion abbott stock option abbvie stock option abbvie anticipate compensation committee grant additional stock option stockbase award employee award dilutive effect abbvie earning share adversely affect market price abbvie common stock time time abbvie issue additional option stockbase award employee abbvie employee benefit plan addition abbvie amend restate certificate incorporation authorize abbvie issue approval abbvie stockholder class series prefer stock designation power preference relative participate optional special right include preference abbvie common stock respect dividend distribution abbvie board director generally determine term class series prefer stock dilute voting power reduce value abbvie common stock example abbvie grant holder prefer stock right elect number abbvie director event happen specify event right veto specify transaction similarly repurchase redemption right liquidation preference abbvie assign holder prefer stock affect residual value common stock certain provision abbvie amend restate certificate incorporation amend restate bylaw delaware law prevent delay acquisition abbvie decrease trading price abbvie common stock abbvie amend restate certificate incorporation amend restate bylaw contain delaware law contain provision intend deter coercive takeover practice inadequate takeover bid make practice bid unacceptably expensive bidder encourage prospective acquiror negotiate abbvie board director attempt hostile takeover provision include inability abbvie stockholder special meeting rule stockholder present proposal nominate director election stockholder meeting right abbvie board issue prefer stock stockholder approval division abbvie board director class director class serve stagger threeyear term provision stockholder remove director cause ability abbvie director stockholder fill vacancy abbvie board director requirement affirmative vote stockholder hold percent abbvie voting stock require amend certain provision abbvie amend restate certificate incorporation abbvie amend restate bylaw relate number term election abbvie director fill board vacancy call special meeting stockholder director officer indemnification provision addition abbvie choose exempt section delaware general corporation law provision delay prevent change control favor section provide subject limited exception person acquire affiliated person acquire percent outstanding voting stock delaware corporation shall engage business combination corporation include merger consolidation acquisition additional share threeyear period follow date person affiliate holder percent corporation outstanding voting stock abbvie believe provision protect stockholder coercive unfair takeover tactic require potential acquiror negotiate abbvie board director provide abbvie board director time assess acquisition proposal provision intend company immune takeover provision apply offer consider beneficial stockholder delay prevent acquisition abbvie board director determine good interest abbvie abbvie stockholder provision prevent discourage attempt remove replace incumbent director agreement abbvie enter abbott require abbott consent assignment abbvie right obligation agreement agreement generally expire year abbvie separation abbott certain agreement continue long term case life product cover agreement consent termination right set forth agreement discourage delay prevent change control consider favorable item certain relationship relate transaction director independence detailed description agreement provision addition acquisition issuance abbvie stock trigger application section internal revenue code tax sharing agreement abbvie require indemnify abbott result tax indemnity obligation discourage delay prevent change control consider favorable cautionary statement forwardlooke statement annual report contain certain forward look statement business strategy market potential future financial performance matter word believe expect anticipate project similar expression generally identify forward look statement speak date statement matter discuss forward look statement subject risk uncertainty factor cause actual result differ materially project anticipated imply forward look statement particular information include item business item risk factor item management discussion analysis financial condition result operation contain forward look statement forward look statement expectation belief future result event express expectation belief base current plan expectation abbvie management express good faith believe reasonable basis assurance expectation belief result achieve accomplished factor cause actual result event differ materially anticipate include matter describe item risk factor item management discussion analysis financial condition result operation abbvie undertake obligation update forwardlooke statement include annual report reflect event circumstance date hereof abbvie require applicable security law item unresolved staff comment item property abbvie corporate office locate north waukegan road north chicago illinois abbvie principal manufacturing plant follow location united states outside united states abbott park illinois campoverde aprilia italy barceloneta puerto rico cork ireland jayuya puerto rico ludwigshafen germany north chicago illinois sligo ireland worcester massachusetts lease property addition abbvie manufacturing facility united states worldwide abbvie believe facility suitable provide adequate production capacity united states include puerto rico abbvie own distribution center abbvie united states research development facility locate abbott park illinois north chicago illinois redwood city california worcester massachusetts outside united states abbvie principal research development facility locate shanghai china ludwigshafen germany note principal plant united states list own abbvie subsidiary abbvie remain manufacturing plant facility own lease abbvie subsidiary abbvie item legal proceeding subject certain exception specify separation agreement abbvie assume liability control pende threatened legal matter relate business include liability claim legal proceeding relate product business discontinue prior distribution assume retain liability indemnify abbott liability arise result assume legal matter january note abbvie involve claim legal proceeding investigation include describe feasible predict outcome pende claim proceeding investigation certainty management opinion ultimate resolution material adverse effect abbvie financial position cash flow result operation case pende abbvie generally allege abbott numerous pharmaceutical company report false pricing information connection certain drug reimbursable medicare medicaid case bring state attorney general generally seek monetary damage andor injunctive relief attorney fee follow case pende state court commonwealth kentucky file september circuit court franklin county kentucky state wisconsin file june circuit court dane county wisconsin state illinois file february circuit court cook county illinois state louisiana file october nineteenth judicial district parish baton rouge louisiana previously report case pende abbvie state court settled previously report certain federal court case consolidated pretrial purpose united states district court district massachusetts multi district litigation rule pharmaceutical industry average wholesale price litigation mdl fourth quarter remain mdl case file august behalf state south carolina settle dismiss prejudice abbvie seek enforce patent right relate testosterone gel drug abbvie sell trademark androgel case file united states district court district delaware february abbvie allege perrigo company perrigo israel pharmaceutical ltd propose generic product infringe abbvie patent seek declaratory injunctive relief pende lawsuit file unimed pharmaceuticals inc solvay pharmaceuticals inc company abbott acquire february consolidated pretrial purpose united states district court northern district georgia multi district litigation rule androgel antitrust litigation mdl case bring private plaintiff federal trade commission ftc generally allege solvay patent litigation involve androgel sham litigation patent litigation settlement agreement relate agreement generic company violate federal state antitrust law state consumer protection unjust enrichment law plaintiff generally seek monetary damage andor injunctive relief attorney fee mdl include individual plaintiff lawsuit supervalu inc unimed pharmaceuticals inc file april united states district court northern district georgia rite aid corp unimed pharmaceuticals inc walgreen unimed pharmaceuticals inc file june united states district court middle district pennsylvania subsequently transfer united states district court northern district georgia seven purport class action meijer inc unimed pharmaceuticals inc rochester drug cooperative inc unimed pharmaceuticals inc louisiana wholesale drug inc unimed pharmaceuticals inc file united states district court northern district georgia fraternal order police unimed pharmaceuticals inc file september united states district court northern district georgia jabo pharmacy inc solvay pharmaceuticals inc file october united states district court eastern district tennessee legrand unimed pharmaceuticals inc file september united states district court northern district georgia health net inc solvay pharmaceuticals inc file february northern district georgia lawsuit bring ftc federal trade commission watson pharmaceuticals inc file united states district court northern district georgia february solvay motion dismiss case partially grant ftc claim plaintiff claim allege sham litigation dismiss decision affirm appeal united states court appeal eleventh circuit december united states supreme court approve ftc october petition review eleventh circuit decision september district court grant summary judgment favor solvay remain claim private plaintiff previously report abbott seek enforce patent right relate fenofibrate tablet drug abbvie sell trademark tricor case file united states district court district new jersey august abbott patent owner laboratoire fourni fournier allege infringement patent seek injunctive relief mylan pharmaceuticals inc mylan inc mylan relate case abbott involve result acquisition fournier laboratory ireland ltd fournier ireland abbott sought enforce additional right relate fenofibrate tablet case file united states district court district new jersey august abbott subsidiary fournier ireland joint patent owner alkerme pharma ireland limited alkerme allege infringement jointlyowne patent seek injunctive relief mylan fourth quarter case settled dismiss prejudice abbvie seek enforce patent right relate ritonavirlopinavir tablet drug abbvie sell trademark kaletra case file united states district court northern district illinois march abbvie allege matrix laboratories inc matrix laboratories ltd mylan inc propose generic product infringe abbvie patent seek declaratory injunctive relief matrix motion november court grant fiveyear stay litigation good cause lift stay show abbvie seek enforce patent right relate ritonavir tablet drug abbvie sell trademark norvir case file united states district court district delaware april abbvie allege roxane laboratories inc roxane propose generic product infringe abbvie patent seek declaratory injunctive relief april roxane file declaratory judgment action united states district court southern district ohio allege abbvie patent invalid infringe roxane propose generic ritonavir product abbvie seek enforce patent right relate niacin extend release tablet drug abbvie sell trademark niaspan case file united states district court district delaware february abbvie allege sun pharmaceutical industries ltd sun pharma global fze generic product infringe abbvie patent seek declaratory injunctive relief second case file united states district court district delaware june abbvie allege sandoz inc propose generic product infringe abbvie patent seek declaratory injunctive relief case file united states district court district delaware january abbvie allege zydus pharmaceuticals usa inc propose generic product infringe abbvie patent seek declaratory injunctive relief fourth case file united states district court district delaware february abbvie allege amneal pharmaceutical propose generic product infringe abbvie patent seek declaratory injunctive relief fifth case file united states district court district delaware march abbvie allege mylan inc mylan pharmaceutical inc propose generic product infringe abbvie patent seek declaratory injunctive relief sixth case file united states district court district delaware march abbvie allege watson laboratories inc propose generic product infringe abbvie patent seek declaratory injunctive relief seventh case file united states district court district delaware june abbvie allege kremer urban pharmaceuticals inc propose generic product infringe abbvie patent seek declaratory injunctive relief abbvie seek enforce certain patent right cover use fully human antitnf alpha antibody methotrexate treat rheumatoid arthritis case file united states district court district massachusetts abbvie allege centocor ortho biotech inc janssen biotech inc product simponi infringe abbvie patent seek damage injunctive relief abbvie seek enforce patent right relate fenofibric acid capsule drug abbvie sell trademark trilipix case file united states district court district new jersey march abbvie subsidiary fournier laboratory ireland ltd allege sandoz inc propose generic product infringe abbvie patent seek injunctive relief item safety disclosure applicable executive officer registrant follow table list abbvie executive officer appoint abbvie corporate officer december age position richard gonzalez chairman board chief executive officer laura schumacher executive vice president business development external affairs general counsel william chase executive vice president chief financial officer carlos alban executive vice president commercial operation john leonard senior vice president chief scientific officer timothy richmond senior vice president human resource azita salekigerhardt phd senior vice president operation thomas hurwich vice president controller gonzalez abbvie chairman chief executive officer serve abbott executive vice president pharmaceutical product group responsible abbott worldwide pharmaceutical business include commercial operation research development manufacturing serve president abbott ventures inc abbott medical technology investment arm gonzalez join abbott hold management position briefly retire include abbott president chief operating officer president chief operating officer abbott medical product group senior vice president president abbott hospital product division hospira inc vice president president abbott health system division divisional vice president general manager abbott diagnostic operation united states canada schumacher abbvie executive vice president business development external affairs general counsel serve abbott executive vice president general counsel corporate secretary senior vice president corporate secretary general counsel schumacher responsible abbott licensing acquisition function office ethic compliance prior appointment general counsel abbott schumacher head abbott litigation department schumacher join abbott chase abbvie executive vice president chief financial officer serve abbott vice president license acquisition vice president treasurer divisional vice president controller abbott international chase join abbott alban abbvie executive vice president commercial operation serve abbott senior vice president proprietary pharmaceutical product global commercial operation senior vice president international pharmaceuticals vice president pharmaceuticals western europe canada vice president western europe canada vice president european operations alban join abbott leonard abbvie senior vice president chief scientific officer serve abbott senior vice president pharmaceutical research development vice president global pharmaceutical research development leonard join abbott richmond abbvie senior vice president human resource serve abbott divisional vice president compensation benefit group vice president talent reward divisional vice president talent acquisition richmond join abbott salekigerhardt abbvie senior vice president operation serve abbott vice president pharmaceutical manufacturing supply divisional vice president quality assurance global pharmaceutical operation salekigerhardt join abbott hurwich abbvie vice president controller serve abbott vice president internal audit divisional vice president controller abbott diagnostics division hurwich join abbott executive officers abbvie elect annually board director officer elect board appoint chairman board officer elect meeting board director hold annual stockholder meeting appoint chairman board meeting officer hold office successor duly elect appoint qualified officer death resignation removal family relationship executive officer list item market registrant common equity relate stockholder matter issuer purchase equity security principal market principal market abbvie common stock new york stock exchange whenissue trading market abbvie common stock begin nyse december regular way trading abbvie common stock begin january prior december public market abbvie common stock abbvie common stock list chicago stock exchange trade regional electronic exchange outside united states abbvie common stock list nyse euronext paris swiss exchange january january high sale price abbvie common stock nyse share low sale price abbvie common stock nyse share shareholder shareholder record abbvie common stock january dividend abbvie expect pay regular cash dividend annual rate share start quarterly dividend pay february time declaration payment dividend abbvie discretion board director depend factor include abbvie financial condition earning capital requirement operating subsidiary covenant associate certain abbvie debt service obligation legal requirement regulatory constraint industry practice ability access capital market factor deem relevant board director abbvie determine pay dividend future assurance continue pay dividend dividend abbvie inc illinois high impact business hib locate federal foreign trade subzone subzone dividend eligible subtraction base income illinois income tax purpose question contact tax advisor item select financial datum follow table set forth abbvie select financial information derive unaudited combine financial statement december year end december audit combine financial statement year end december december historical financial information present indicative result operation financial position obtain abbvie independent company period show abbvie future performance independent company select financial information read conjunction combine financial statement accompany note management discussion analysis financial condition result operation year end december millions share datum combine statement earning datum net sale net earning basic diluted earning common share basic diluted average share outstandinga combine balance sheet datum total asset longterm debt lease obligationsb january abbott laboratories distribute million share abbvie common stock computation basic diluted share period december calculate share distribute january refer note combine financial statement information earning common share include current portion longterm debt lease obligation item management discussion analysis financial condition result operation follow discussion analysis financial position result operation abbvie inc year period end december commentary read conjunction combine financial statement accompany note appear item financial statement supplementary data executive overview company overview abbvie inc abbvie company global researchbase biopharmaceutical company abbvie develop market advanced therapy address world complex disease abbvie product treat rheumatoid arthritis psoriasis crohn disease hiv cystic fibrosis complication low testosterone thyroid disease parkinson disease ulcerative colitis complication associate chronic kidney disease indication abbvie pipeline promise new medicine include compound indication phase phase iii development important medical specialty immunology renal care hepatitis virus hcv woman health oncology neuroscience include multiple sclerosis alzheimer disease abbvie approximately employee product sell country abbvie operate business segment pharmaceutical product january abbvie independent company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott shareholder abbott shareholder record close business december receive share abbvie common stock abbott common share hold record date abbvie incorporate delaware april comprise abbott researchbase pharmaceutical business abbvie registration statement form declare effective securities exchange commission december abbvie common stock begin trade regularway ticker symbol abbv new york stock exchange january refer basis presentation section information abbvie product include broad line adult pediatric pharmaceutical manufacture market sell worldwide generally sell directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer distribution center public warehouse outside united states sale directly customer distributor depend market serve certain product market copromoted company humira worldwide sale increase billion compare billion billion abbvie begin worldwide launch humira rheumatoid arthritis follow launch additional indication united states additional indication european union humira receive approval treatment moderately severely active ulcerative colitis adult patient inadequate response conventional therapy european commission april food drug administration fda october july humira receive approval european commission treatment severe axial spondyloarthritis adult patient xray evidence structural damage november receive approval european commission treatment pediatric patient age year severe active crohn disease fail intolerant contraindication conventional therapy abbvie study additional indication humira substantial research development selling support continue dedicated maximize worldwide potential humira abbvie forecast low doubledigit growth worldwide humira sale acquisition solvay pharmaceuticals business solvay certain product right billion february add new product include right androgel creon abbvie portfolio generic competition begin november tricor expect begin second half niaspan second half early trilipix result sale abbvie combine lipid franchise include tricor trilipix niaspan simcor billion billion expect total billion decrease sale zemplar million million reflect impact change reimbursement regulation result health care reform legislation austerity measure implement european country reduce health care spending affect pharmaceutical pricing country year present strategic objective abbvie longterm strategy maximize exist portfolio new indication share gain increase reach geographic expansion underserved market advance new product pipeline successfully execute longterm strategy abbvie focus expand humira sale advance pipeline expand presence emerge market manage product portfolio maximize value abbvie expect continue drive strong humira sale growth way abbvie seek expand humira patient base apply regulatory approval new indication humira treat condition axial peripheral spondyloarthritis uveitis abbvie seek drive humira sale growth expand market share presence underserve market research development effort continue focus significant portion expenditure compound immunology oncology neuroscience pain management virology renal disease woman health abbvie goal bring market product demonstrate strong clinical performance patient economic value payor current research development project describe research development section abbvie plan continue make investment key emerge market include brazil china mexico russia continue penetration humira leading product expect help drive growth market abbvie continue investment product durable sale make adjustment necessary increase value product portfolio abbvie plan achieve objective variety way depend product circumstance example identify supply chain efficiency pursue additional indication optimize residual value product reach end exclusivity abbvie believe approach allow company maintain strong operating margin research development innovation scientific productivity continue key strategic priority abbvie abbvie longterm success depend great extent ability continue discover develop innovative pharmaceutical product acquire collaborate compound currently development biotechnology pharmaceutical company abbvie pipeline compound indication phase iii development individually collaboration license agreement focus therapeutic area include virology renal disease neuroscience oncology immunology woman health virology abbvie release positive phase phase iib result interferonfree study treatment hcv october abbvie initiate comprehensive phase iii program genotype hcv involve combination abt protease inhibitor hcv infection abt polymerase inhibitor abt nsa inhibitor renal disease abbvie renal care pipeline include atrasentan treatment diabetic chronic kidney disease ckd phase iib study atrasentan patient diabetic kidney disease begin june complete result present atrasentan potentially compound launch treat diabetic nephropathy specifically target albuminuria slow progression ckd abbvie investigate abt phase iib development treatment acute kidney injury associate major surgery abbvie enter agreement reata pharmaceuticals inc reata exus right exclude certain asian market bardoxolone methyl investigational treatment ckd global phase iii clinical trial initiate june october reata informed abbvie discontinuing phase iii clinical study discontinuation base recommendation study independent datum monitor committee safety concern excess adverse event mortality bardoxolone methyl arm reata abbvie closely examine datum study determine appropriate path forward development bardoxolone methyl ckd indication neuroscience pain abbvie clinical study underway multiple compound target receptor brain help regulate mood memory neurological function condition include schizophrenia pain alzheimer disease multiple sclerosis abbvie collaborate biogen idec develop daclizumab treatment relapse remit form common form affect nearly percent newly diagnose patient daclizumab anticd monoclonal antibody currently phase iii development abbvie investigate abt annr modulator alzheimer disease cognitive deficit schizophrenia additional phase iib study begin march development abt treatment multiple pain indication suspend base fda classwide feedback levodopacarbidopa intestinal gel complete phase iii program abbvie pursue regulatory approval united states product sell duodopa outside united states oncology abbvie focus development target treatment inhibit tumor growth improve response common cancer therapy abbvie oncology pipeline include follow elotuzumab anticd antibody treatment multiple myeloma collaboration bristolmyer squibb phase iii development begin june veliparib parpinhibitor phase iib study brcamutate breast cancer treat chemotherapy initiate veliparib phase evaluation treatment variety solid tumor include brain metastasis nonsmallcell lung cancer treat radiation therapy non smallcell lung cancer combination chemotherapy abt nextgeneration bcl inhibitor development chronic lymphocytic leukemia expect start phase iii evaluation molecular target explore antibodydrug conjugate approach link antitarget antibodie potent cytotoxic agent woman health abbvie develop novel oral gonadotropinrelease hormone gnrh antagonist elagolix collaboration neurocrine bioscience treatment endometriosisrelate pain uterine fibroid phase iii study endometriosis begin mid phase iia study uterine fibroid initiate november immunology abbvie develop additional indication humira number nextgeneration program underway address immunemediate condition include follow dual variable domain immunoglobulin dvdig technology represent approach target multiple diseasecausing antigen single biologic agent proprietary technology lead nextgeneration biologic treatment complex condition cancer rheumatoid arthritis multiple pathway involve disease abbvie collaborate biotest anticd biologic know tregalizumab compound currently phase iib clinical trial rheumatoid arthritis psoriasis glpg nextgeneration oral janus kinase jak inhibitor develop galapagos collaboration enter quarter glpg currently phase iib development treat rheumatoid arthritis able address autoimmune disease fourth quarter abbvie enter collaboration reata joint development commercialization secondgeneration oral antioxidant inflammation modulator additional indication formulation abbvie continue dedicate effort expand indication humira include field rheumatology peripheral spondyloarthritis axial spondyloarthritis pediatric enthesitis relate arthritis gastroenterology pediatric crohn disease pediatric ulcerative colitis dermatology pediatric psoriasis hidradenitis suppurativa ophthalmology uveitis phase iii trial ongoing preparation regulatory application uveitis united states european union peripheral axial spondyloarthritis united states peripheral spondyloarthritis european union hidradenitis suppurativa united states european union follow registration approval occur january european union approval pediatric crohn disease obtain november ulcerative colitis european union approval obtain april approval united states obtain september axial spondyloarthritis approval european union obtain july registration submission united states november new formulation abbvie exist pharmaceutical product approve include month month strength lupron depot united states june august respectively united states new strength creon approve june androgel approve april additional registration submission new strength creon september give numerous source potential future growth individual project expect material cash flow result operation year factor consider include expense project incurred project year relative abbvie total expense qualitative factor marketplace perception impact new product abbvie overall market position delay abbvie activity expect material impact operation aggregate cost complete numerous pharmaceutical project currently development expect material total cost complete depend abbvie ability successfully complete project rate project advance nature extent costshare arrangement ultimate timing completion give potential significant delay high rate failure inherent research development new pharmaceutical product possible accurately estimate total cost complete project currently development abbvie plan continue manage portfolio project achieve research development spend equal approximately percent net sale year abbvie regularly accumulate management decision base total expense incur particular development phase give period basis presentation abbvie historical combine financial statement prepare standalone basis derive abbott consolidated financial statement accounting record researchbase pharmaceutical business abbott abbvie period present combined financial statement reflect abbvie financial position result operation cash flow business operate abbott prior distribution conformity generally accept accounting principle combine financial statement principally represent historical result operation asset liabilitie abbott proprietary pharmaceutical product segment historical financial statement include allocation certain asset liability historically hold abbott corporate level specifically identifiable allocable abbvie prior cash equivalent shortterm investment restrict fund hold abbott allocate abbvie cash investment hold entity transfer abbvie december cash equivalent shortterm investment reflect abbvie direct ownership asset prior longterm debt shortterm borrowing allocate abbvie debt record abbott directly attributable guarantee abbvie abbvie issue billion longterm debt maturity range year billion commercial paper reflect abbvie combine balance sheet december intracompany abbvie transaction eliminate december intercompany transaction abbvie abbott consider effectively settle combine financial statement time transaction record total net effect settlement intercompany transaction reflect combined statement cash flow financing activity combine balance sheet net parent company investment abbvie december outstanding intercompany transaction abbvie abbott reflect abbott laboratories abbott laboratory combine balance sheet abbvie historical financial statement include allocation expense relate certain abbott corporate function include senior management legal human resource finance information technology quality assurance expense allocate abbvie base direct usage benefit identifiable remainder allocate pro rata basis revenue headcount square footage number transaction measure abbvie consider expense allocation methodology result reasonable reflection utilization service provide benefit receive company period present allocation reflect expense company incur independent publiclytraded company period present subsequent separation abbvie expect incur additional cost associate independent publiclytrade company primarily high charge past abbott service continue provide transition basis newly establish expand corporate function abbvie expect incur onetime cost primarily establish certain standalone abbvie function information technology system establish infrastructure outside united states complete separation certain country portion expenditure capitalize depreciated asset useful life remainder expense incur depend nature cost abbvie believe cash flow operation sufficient fund additional corporate expense historical financial statement necessarily include expense incur abbvie separate standalone entity necessarily reflect abbvie result operation financial position cash flow abbvie standalone company period present refer note description transaction abbvie abbott result operation net sale percent change actual constant currency currency rate rate year end millions united states international net sale increase sale primarily high humira sale partially offset impact unfavorable foreign currency entry generic tricor fourth quarter follow table detail sale key product percent change actual constant currency currency rate rate year end december millions humira united states international total androgel united states tricortrilipix united states kaletra united states international total niaspan united states synagis united states international total lupron united states international total sevoflurane united states international total synthroid united states norvir united states international total zemplar united states international total creon united states total comparison present constant currency rate reflect comparative local currency sale prior year foreign exchange rate measure provide information change net sale assume foreign currency exchange rate change prior current period abbvie believe nongaap measure change net sale constant currency rate conjunction gaap measure change net sale actual currency rate provide complete understand company operation facilitate analysis company result operation particularly evaluate performance period increase humira sale reflect market growth high market share country high pricing certain geography humira receive approval european commission april fda october treatment moderately severely active ulcerative colitis adult patient inadequate response conventional therapy approval european commission humira selfinjectable biologic therapy treatment moderately severely active ulcerative colitis adult july humira receive approval european commission treatment severe axial spondyloarthritis adult patient xray evidence structural damage november humira receive approval european commission treatment pediatric patient age year severe active crohn disease fail intolerant contraindication conventional therapy approval mark ninth indication humira european union decline tricor trilipix niaspan sale reflect softness overall brand cholesterol market introduction generic version tricor united states market november result sale abbvie combine lipid franchise include tricor trilipix niaspan decline percent compare license agreement trilipix generic competition begin january certain circumstance license commence early july agreement relate abbvie niacin product acquire kos pharmaceuticals acquisition niaspan subject generic competition september decline kaletra revenue primarily low market share country impact competition increase androgel sale reflect high price market share gain launch androgel second quarter volume growth testosterone replacement market androgel hold number market share position androgel sale expect impact generic competition sale sevoflurane impact generic competition sale zemplar impact change reimbursement regulation result health care reform legislation gross margin percent change year end december millions gross margin net sale increase gross profit margin primarily product mix improve efficiency high price certain geography favorable impact foreign currency partially offset pricing pressure market improvement reflect low amortization expense intangible asset impact restructuring program implement realign manufacturing operation change governmental rebate program continue negative effect gross profit margin health care reform legislation united states result increase additional medicaid rebate begin additional rebate relate medicare donut hole begin negatively affect abbvie business negative impact rebate result health care reform legislation grow million approximately million sell general administrative percent change year end december million sell general administrative net sale sell general administrative sga expense include million cost associate separation abbvie abbott sga expense include litigation charge million billion respectively relate depakote investigation sga expense include million million respectively relate restructure integration project associate acquisition solvay refer note information depakote charge note information solvay acquisition exclude separation cost litigation charge solvayrelate restructure integration cost year sga expense increase percent percent percent respectively increase sga expense threeyear period primarily increase selling marketing support new exist product include continue spend humira impact pharmaceutical fee impose health care reform legislation research development acquire inprocess research development percent change year end december million research development net sale acquire inprocess research development increase reflect continued pipeline spending program biologic neuroscience virology million milestone payment relate product development treatment chronic kidney disease expense include restructuring charge million million acquire inprocess research development iprd expense include charge million acquisition abt charge million result enter global collaboration develop commercialize oral nextgeneration jak inhibitor charge million result enter twoyear collaboration agreement research develop commercialize compound antibodydrug conjugate approach iprd expense include charge million achievement developmental milestone licensing agreement treatment ckd charge million million enter collaboration agreement secondgeneration oral antioxidant inflammation modulator anticd biologic treatment rheumatoid arthritis psoriasis respectively iprd expense include charge million million result enter licensing agreement treatment ckd enter collaboration agreement treatment endometriosis respectively interest expense interest expense net million comprise primarily interest expense outstanding debt bridge facility fee relate separation abbott partially offset interest income november abbvie issue billion longterm debt maturity range year abbvie enter interest rate swap financial institution convert billion fix rate interest rate debt float interest rate debt addition abbvie issue billion commercial paper fourth quarter abbvie expect incur approximately million net interest expense income expense income expense net include income million resolution contractual agreement loss million impairment equity security income expense net include loss million million fair value adjustment accretion contingent consideration relate acquisition solvay income expense net include ongoing contractual payment takeda associate conclusion tap pharmaceutical products inc joint venture income tax expense income tax rate percent percent percent income taxis include recognition tax benefit total approximately million million respectively result favorable resolution tax position pertain prior year income taxis reflect nondeductibility litigation reserve exclude discrete item effective tax rate statutory federal income tax rate percent principally benefit low statutory tax rate tax exemptions puerto rico foreign tax jurisdiction reduce tax rate percentage point respectively abbvie expect effective income tax rate approximately percent exclude discrete item october puerto rico enact legislation assess excise tax begin certain product manufacture puerto rico tax levy gross inventory purchase entities puerto rico include cost product sell majority tax creditable income tax purpose excise tax total approximately million million respectively transition abbott cost operate independent company combine financial statement reflect operating result financial position abbvie operate abbott independent company abbvie incur additional ongoing operating expense operate independent company cost include cost corporate headquarters function incremental information technologyrelate cost incremental cost operate standalone office infrastructure outside united states order establish standalone function abbvie incur nonrecurre expense capital expenditure transition service agreement united states cover certain corporate support service abbvie historically receive abbott service include information technology account payable payroll financial function engineering support facility quality assurance support administrative service term service agreement vary activity agreement facilitate separation allow abbvie operate independently prior establish standalone office system organization operating cost information technology system maintain abbott allocate abbvie basis management believe reasonable include allocation abbvie proportionate share fix operating cost independent company abbvie information technology operating cost high cost allocate historical combine financial statement addition abbvie incur nonrecurring expense capital expenditure establish independent information technology system market outside united states abbvie currently sufficient office infrastructure operate transition service agreement abbott abbott enter transition service agreement abbvie provide service outside united states include office service certain country year separation office service provide include information technology account payable payroll receivables collection treasury financial function order entry warehouse administrative service transition service agreement allow abbvie operate international pharmaceutical business independently prior establish standalone office infrastructure country transition abbott abbvie incur nonrecurring expense expand international infrastructure addition certain international market marketing authorization sell abbvie product continue hold abbott postseparation authorization transfer applicable regulatory channel practicable estimate cost incur period present historical financial statement function describe actual cost incur abbvie operate standalone company period depend factor include organizational design outsource strategic decision relate corporate function information technology international office infrastructure financial position liquidity capital resource year end december million cash flow provide byused operating activity invest activity financing activity strong cash flow operating activity year drive high net earning focus work capital management abbvie record noncash charge billion accrue liability accrue litigation reserve relate claim abbvie previous sale marketing activity depakote abbvie payment billion settle claim abbvie issue senior note billion november billion commercial paper december abbott guarantee senior note terminate distribution abbvie common stock shareholder abbott separation january senior note maturity range year redeem time float rate note senior note series redemption price equal principal plus makewhole premium balance commercial paper outstanding december billion weight average interest rate abbvie retire issue additional commercial paper meet liquidity requirement need historically cash flow financing activity represent cash transaction abbott company cash equivalent shortterm investment increase million december million december abbott contribute approximately billion cash newly form abbvie entity abbvie distribute billion cash debt security abbott subsequent separation effective january abbvie long participate cash management funding arrangement abbott significant portion cash equivalent december consider reinveste indefinitely foreign subsidiary abbvie expect reinvestment affect liquidity capital resource fund need operation united states abbvie require accrue pay income taxis repatriate fund abbvie believe sufficient source liquidity support assumption disclose undistribute earning december consider reinveste indefinitely february company announce billion stock repurchase program effective immediately purchase abbvie share time time management discretion plan time limit discontinue time dividend share pay february stockholders record january board director declare quarterly cash dividend share stockholder record april payable abbvie expect pay regular cash dividend annual rate share time declaration payment dividend discretion board director depend factor include abbvie financial condition earning capital requirement operating subsidiary covenant associate certain abbvie debt service obligation legal requirement regulatory constraint industry practice ability access capital market factor deem relevant board director substantially abbvie trade receivables greece portugal italy spain governmental health system global economic condition liquidity issue country result continue result delay collection receivables credit loss time collect outstanding receivable increase exception greece collection times improve relative amount year past decrease relative outstanding net governmental receivables country december follow net receivables year net receivable past million greece portugal italy spain total exception greece abbvie historically collect outstanding receivables country abbvie continue monitor creditworthiness customer locate geographic area establish allowance account receivable probable collect addition closely monitor economic condition budgetary fiscal development country abbvie regularly communicate customer status receivable balance include payment plan obtain positive confirmation validity receivables abbvie monitor potential periodically utilize factoring arrangement mitigate credit risk receivable include arrangement historically material total outstanding receivables government funding unavailable country significant adverse change reimbursement practice occur abbvie able collect entire balance credit facility access capital credit rating credit facility abbvie currently billion unsecured fiveyear revolve credit facility syndicate lender enter july support commercial paper borrowing date separation january abbott obligation facility relieve abbvie sole obligor credit facility enable company borrow fund float interest rate december company compliance credit facility covenant commitment fee new credit facility material amount outstanding credit facility december access capital company intend fund shortterm longterm financial obligation mature cash hand future cash flow operation issue additional debt company ability generate cash flow operation issue debt enter financing arrangement acceptable term adversely affect material decline demand company product solvency customer supplier deterioration company key financial ratio credit rating material unfavorable change business condition current time company believe sufficient financial flexibility issue debt enter financing arrangement attract longterm capital acceptable term support company growth objective credit rating late october moody investor service standard poor corporate assign rating baa respectively abbvie unfavorable change rating adverse impact future financing arrangement affect company ability draw credit facility result acceleration schedule maturities company outstanding debt contractual obligation follow table summarize abbvie estimate contractual obligation december million total year year year year shortterm borrowing longterm debt capital lease obligation include current maturity interest longterm debta purchase obligation otherb longterm liabilitiesc total include estimate future interest payment longterm debt security interest payment debt calculate future period interest rate effect end project interest payment include relate effect interest rate swap agreement certain project interest payment differ future base change float interest rate factor event project interest payment pertain obligation agreement outstanding december refer note discussion company debt instrument relate interest rate agreement outstanding december include company significant unconditional purchase obligation commitment exceed company project requirement normal course business exclude pension postemployment benefit relate deferred compensation cash outflow time fund uncertain dependent future movement interest rate investment return change law regulation variable include component longterm liability include restructuring expect payment relate contingent sale base payment recognize acquisition solvay refer note information abbvie enter collaboration arrangement party require future milestone payment party contingent achievement certain development regulatory commercial milestone individually arrangement material annual reporting period milestone multiple product cover arrangement happen reach reporting period aggregate charge expense material result operation period business perspective payment view positive signify product successfully move development generating likely generate cash flow product sale possible predict reasonable certainty milestone achieve timing achievement result potential payment include table contractual obligation refer note discussion collaboration arrangement critical accounting policy preparation financial statement accordance generally accept accounting principle require use estimate assumption affect report amount asset liability report amount revenue expense summary company significant accounting policy include note certain policy consider critical significantly impact company financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain actual result vary estimate revenue recognition abbvie recognizes revenue persuasive evidence arrangement exist delivery occur sale price fix determinable collectability sale price reasonably assure revenue product sale recognize title risk loss pass customer rebate abbvie provide rebate pharmacy benefit management company state agency administer federal medicaid program insurance company administer medicare drug plan wholesaler group purchasing organization government agency private entity rebate amount usually base volume purchase contractual statutory price product type rebate factor calculation accrual rebate include identification product sell subject rebate customer government agency price term apply rebate estimate lag time sale payment rebate historical trend rebate adjust current change abbvie estimate rebate pay record liability reduction gross sale abbvie record sale product settlement rebate generally occur month sale abbvie regularly analyze historical rebate trend make adjustment reserve change trends term rebate program rebate chargeback accruals record period relate sale reflect reduction sale rebate chargeback total billion billion billion respectively percent percent percent respectively gross sale subject rebate onepercentage point increase percentage rebate relate gross sale decrease net sale million abbvie consider percentage point increase reasonably likely increase percentage rebate relate gross sale allowance cash discount return charge gross sale million million million respectively management analyze adequacy end rebate accrual balance quarter united states significant charge gross sale medicaid medicare rebate pharmacy benefit manager rebate wholesaler chargeback medicaid rebate relate federal medicaid program administer state agency rebate provide participate state local government entity law regulation case supplemental rebate provide state contractual agreement medicare rebate negotiate manage care organization manage prescription drug plan cover medicare drug benefit pharmacy benefit manager rebate arise contractual agreement private health care plan seek reduce cost negotiate discount pharmaceutical manufacturer wholesaler chargeback programs wholesaler charge abbvie difference price pay wholesaler abbvie price pay end customer wholesaler contractual discount agreement negotiate abbvie end customer order evaluate adequacy end accrual balance type rebate management use internal external datum estimate level inventory distribution channel rebate claim processing lag time rebate external data source estimate inventory distribution channel include inventory level periodically report wholesaler management estimate process lag time base periodic sampling claim datum estimate price rebate percentage system calculation track sale product customer estimate contractual statutory price abbvie system calculation develop time rebate significant abbvie believe reliable follow table analysis large rebate accrual chargeback allowance comprise approximately percent combine rebate provision charge revenue remain rebate provision charge gross sale significant determination operate earning medicaid pharmacy benefit medicare manager wholesaler millions rebate rebate chargeback balance january provision payment balance december provision payment balance december provision payment balance december historically adjustment prior year rebate accrual material net income abbvie employ technique verify accuracy claim submit possible work organization submit claim gain insight change affect rebate amount medicaid medicare government agency program calculation rebate involve interpretation relevant regulation subject challenge change interpretation cash discount return cash discount reliably estimate product return reliably estimate abbvie historical return low sale return term sale term remain relatively unchanged period pension postemployment benefit abbvie employee participate pension postemployment health care plan sponsor abbott abbvie financial statement plan account multiemployer benefit plan liability reflect abbvie combine balance sheet unfunded contribution end report period effective january connection separation abbvie abbott abbvie record net benefit plan obligation transfer abbott abbvie combine statement earning include expense allocation benefit expense fund intercompany transaction abbott reflect net parent company investment abbvie certain pension plan germany puerto rico canada ireland united kingdom united states direct obligation abbvie record combine financial statement december abbvie engage outside actuary assist determination obligation cost plan valuation fund status net periodic benefit cost plan calculate actuarial assumption significant assumption review annually include discount rate expect longterm rate return plan asset health care cost trend rate discount rate select base current market rate highquality fixedincome investment december year expect longterm rate return base asset allocation historical performance current view expect future return health care cost trend rate select review historical trend current view project future health care cost increase significant assumption determine calculation disclose note combine financial statement income taxis abbvie combine financial statement income tax expense defer tax balance calculate separate tax return basis abbvie operation historically include tax return file respective abbott entities abbvie business future stand company abbvie file tax return behalf defer taxis effective tax rate differ historical period abbvie abbott enter tax sharing agreement effective date separation january tax contingency prior separation abbott indemnify hold abbvie harmless tax position settle amount excess record liability abbvie benefit prior tax position resolve favorably record amount litigation company subject contingency legal proceeding claim arise normal course business refer note information loss contingency provision record probable loss management good estimate loss good estimate minimum loss contingency record accordingly abbvie initially unable develop good estimate loss minimum zero record information know minimum loss increase result additional loss provision good estimate result additional loss provision occasionally good estimate change low event result expectation favorable outcome previously expect significant litigation reserve december valuation intangible asset goodwill abbvie acquire continue acquire significant intangible asset connection business combination abbvie record fair value transaction involve purchase sale intangible asset occur frequency company pharmaceutical industry valuation usually base discount cash flow analysis incorporate stage completion discount cash flow model require assumption time future net cash flow risk cost capital terminal value market participant factor significantly affect value intangible asset iprd acquire business combination capitalize indefinitelive intangible asset regulatory approval obtain time account definitelived asset amortize estimate useful life iprd acquire transaction business combination expense immediately deem alternative future use payment party subsequent regulatory approval capitalize amortize remain useful life abbvie review recoverability definitelive intangible asset event change circumstance indicate carry value asset recoverable goodwill indefinitelive intangible asset relate iprd review impairment annually event result impairment occur refer note combine financial statement information impairment review company use estimate future cash flow approach require significant judgment respect future volume revenue expense growth rate change work capital use foreign currency exchange rate selection appropriate discount rate asset grouping assumption estimate estimate assumption consistent company business plan market participant view company similar company use alternative estimate assumption increase decrease estimate fair value asset potentially result different impact company result operation actual result differ company estimate december goodwill intangible asset total million million respectively amortization expense intangible asset million million million respectively impairment goodwill result impairment test indicate fair value report unit substantially excess carrying value abbvie record impairment charge million million respectively certain project development certain regulatory matter legislative issue quarter patient protection affordable care act health care education reconciliation act collectively refer health care reform legislation sign law united states health care reform legislation include increase basic medicaid rebate rate percent percent extend rebate drug provide medicaid manage care organization start additional rebate incur related medicare coverage gap donut hole medicare medicaid rebate change continue negative effect abbvie gross profit margin future year abbvie begin record annual fee impose health care reform legislation company sell brand prescription drug specify government program annual fee total approximately million base ratio certain abbvie sale compare total sale cover entity multiply fix dollar specify legislation year fee tax deductible include sga expense abbvie market highly competitive subject substantial government regulation abbvie expect debate continue availability method delivery payment health care product service possible predict extent abbvie health care industry general adversely affect factor future complete discussion factor contain item business item risk factor item quantitative qualitative disclosure market risk company expose risk earning cash flow equity adversely impact change foreign exchange rate interest rate certain derivative instrument available costeffective basis hedge company underlie economic exposure refer note information company financial instrument hedge strategy foreign currency risk abbvie primary net foreign currency translation exposure euro british pound japanese yen canadian dollar abbvie foreign subsidiary enter foreign currency forward exchange contract manage exposure change foreign exchange rate anticipate intercompany transaction denominate currency functional currency local entity contract designate cash flow hedge variability cash flow change foreign currency exchange rate markedtomarket result gain loss reflect accumulated comprehensive income loss defer gain loss contract include cost product sell time product sell party generally month december abbvie hold billion million respectively contract mature follow calendar year abbvie enter foreign currency forward exchange contract manage exposure foreign currency denominate trade payable receivables contract designate hedge markedtomarket result gain loss reflect income generally offset loss gain foreign currency exposure manage december abbvie hold billion billion respectively foreign currency forward exchange contract follow table reflect total foreign currency forward contract outstanding december fair fair weighted carrying weight carry average value average value contract exchange receivable contract exchange receivable million rate payable rate payable receive primarily dollar exchange follow currency euro british pound japanese yen canadian dollar currency total company estimate percent appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million december realize appreciation negatively affect earning remain life contact percent appreciation believe reasonably possible nearterm change foreign currency currency restriction enact venezuela require abbvie obtain approval venezuelan government exchange venezuelan bolivar dollar require exchange official exchange rate establish government effective february venezuelan government devalue official exchange rate expect material impact financial result company interest rate risk interest rate swap manage company exposure change interest rate fixedrate debt effect hedge change fix interest rate variable rate abbvie use derivative instrument interest rate swap manage exposure change interest rate investment security december abbvie interest rate hedge contract total billion company estimate increase interest rate basis point decrease fair value interest rate swap contract approximately million realize fair value reduction affect earning remain life contract company estimate increase basis point longterm interest rate decrease fair value longterm debt million basis point change believe reasonably possible nearterm change rate market price sensitive investment abbvie hold availableforsale equity security strategic technology acquisition market value investment approximately million million december respectively abbvie monitor investment temporary decline market value charge impairment loss income temporary decline value occur hypothetical percent decrease share price investment immaterial decrease fair value december percent decrease believe reasonably possible nearterm change share price nonpublicly trade equity security abbvie hold equity security strategic technology acquisition trade public stock exchange carry value investment approximately million million december respectively abbvie monitor investment temporary decline market value charge impairment loss income temporary decline estimate value occur item financial statement supplementary datum combine financial statement combine statement earning combine statement comprehensive income combine statement cash flow combine balance sheet combine statement parent company equity note combine financial statement report independent register public accounting firm abbvie inc subsidiary combine statement earning year end december millions share datum net sale cost product sell sell general administrative research development acquire inprocess research development total operating cost expense operate earning interest expense net net foreign exchange gain loss income expense net earning income tax income tax expense net earning share datum basic diluted earning sharea january abbott laboratories distribute million share abbvie common stock computation basic diluted earning common share period december calculate share distribute january accompany note integral combine financial statement abbvie inc subsidiary combine statement comprehensive income year end december million net earning foreign currency translation gain loss adjustment pension postemployment benefit net tax benefit unrealize loss gain marketable equity security net tax benefit expense hedging activity net tax benefit expense comprehensive loss comprehensive income accompany note integral combine financial statement abbvie inc subsidiary combine statement cash flow year end december million bracket denote cash outflow cash flow operating activity net earning adjustment reconcile earning net cash operating activity depreciation amortization intangible asset stockbase compensation acquire inprocess research development change operate asset liability net acquisition account receivable inventory prepaid expense asset account payable liability cash flow operating activity cash flow invest activity acquisition investment net cash acquire acquisition property equipment release deposit restrict fund purchase investment security sale investment security cash flow invest activity cash flow financing activity proceed issuance longterm debt net change shortterm borrowing net transaction abbott laboratory exclude noncash item cash flow financing activity effect exchange rate change cash equivalent net increase cash equivalent cash equivalent begin year cash equivalent end year accompany note integral combine financial statement abbvie inc subsidiary combine balance sheet december million asset current asset cash equivalent shortterm investment account receivable abbott laboratory inventory defer income taxis prepaid expense total current asset investment net property equipment intangible asset net amortization goodwill asset total asset liability net parent company investment abbvie inc current liability shortterm borrowing current maturity longterm debt lease obligation account payable accrue liability abbott laboratories total current liability longterm liabilities longterm debt lease obligation commitment contingency parent company equity net parent company investment abbvie inc accumulate comprehensive loss total parent company equity total liability net parent company investment abbvie inc accompany note integral combine financial statement abbvie inc subsidiary combine statement parent company equity net parent accumulate company comprehensive year end december million investment income total balance january net earning net transaction abbott laboratorie comprehensive loss balance december net earning net transaction abbott laboratorie comprehensive loss balance december net earning net transaction abbott laboratories assumption accumulate unrealized loss pension post employment benefit net tax benefit comprehensive loss balance december accompanying note integral combine financial statement abbvie inc subsidiary note combine financial statement note basis presentation principal business abbvie inc abbvie company discovery development manufacture sale broad line proprietary pharmaceutical product substantially abbvie sale wholesaler outside united states product sell primarily health care provider distributor depend market serve january abbvie independent company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott shareholder abbvie incorporate delaware april abbott board director approve distribution share abbvie november abbvie registration statement form declare effective securities exchange commission december january abbott shareholder record close business december receive share abbvie common stock share abbott common stock hold record date abbvie common stock begin trade regularway ticker symbol abbv new york stock exchange january accompany combined financial statement prepare standalone basis derive abbott consolidated financial statement accounting record researchbase pharmaceutical business abbott abbvie period present combined financial statement reflect abbvie financial position result operation cash flow business operate abbott prior distribution conformity generally accept accounting principle combine financial statement include allocation certain asset liability historically hold abbott corporate level specifically identifiable allocable abbvie prior cash equivalent shortterm investment restrict fund hold abbott allocate abbvie asset hold entity transfer abbvie december abbvie combine balance sheet reflect direct holding abbvie legal entity intracompany transaction account eliminate prior intercompany transaction abbvie abbott consider effectively settle combine financial statement time transaction record result total net effect settlement intercompany transaction reflect combined statement cash flow financing activity combine balance sheet net parent company investment abbvie december outstanding intercompany transaction abbvie abbott reflect abbott laboratories abbott laboratory combine balance sheet abbvie combine financial statement include allocation expense relate certain abbott corporate function include senior management legal human resource finance information technology quality assurance expense allocate abbvie base direct usage benefit identifiable remainder allocate pro rata basis revenue headcount square footage number transaction measure abbvie consider expense allocation methodology result reasonable period present allocation indicative actual expense incur abbvie operate independent publiclytraded company period present abbvie employee participate benefit stockbase compensation program maintain abbott portion cost program include abbvie financial statement abbvie combine balance sheet include equity relate stockbase compensation plan note note description account postemployment benefit stockbase compensation respectively note summary significant accounting policy use estimate financial statement prepare accordance generally accept accounting principle united states necessarily include amount base estimate assumption management actual result differ amount significant estimate include amount sale rebate income taxis pension postemployment benefit valuation intangible asset goodwill litigation financial instrument inventory account receivable exposure revenue recognition abbvie recognize revenue persuasive evidence arrangement exist delivery occur sale price fix determinable collectability sale price reasonably assure revenue product sale recognize title risk loss pass customer provision discount rebate sale incentive customer return adjustment provide period relate sale record sale incentive customer material historical datum readily available reliable estimating reduction gross sale revenue launch new product improve version exist product shipment excess customer normal requirement record condition note meet situation management record return reserve revenue necessary sale product right marketable product record revenue disposition right research development cost internal research development cost expense incur clinical trial cost incur party expense contract work perform contingent milestone payment party research development collaboration precommercialization milestone milestone payment obligation expense milestone result achieve payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible asset net accumulate amortization advertising cost associate advertising expense year incur include sell general administrative expense sga advertising expense million million million respectively pension postemployment benefit abbvie record annual expense relate pension benefit postemployment plan base calculation include actuarial assumption include discount rate assume asset rate return compensation increase turnover rate health care cost trend rate abbvie review actuarial assumption annual basis make modification assumption base current rate trend actuarial loss gain amortize remain service attribution period employee corridor method accordance rule account postemployment benefit difference expect longterm return plan asset actual annual return amortize fiveyear period abbvie employee participate define benefit pension postemployment plan sponsor abbott include participant abbott business plan account multiemployer plan historical financial statement abbvie result asset liability record abbvie historical combine balance sheet recognize fund status plan subsequent separation abbott abbvie portion define benefit pension plan separate abbott define benefit pension plan time fund status plan reflect abbvie combine balance sheet december measurement date addition participation define benefit pension post employment plan sponsor abbott abbvie sole sponsor certain define benefit pension postemployment plan fund status plan record combine balance sheet abbvie december refer note information abbvie pension postemployment plan income taxis income taxis earning reflect annual effective rate include charge interest penalty defer income taxis provide tax effect temporary difference tax basis asset liability reported amount financial statement base enact tax law rate combine balance sheet december appropriately revise increase defer tax liability longterm liabilitie million decrease defer tax asset asset million decrease net parent company investment abbvie million properly reflect temporary difference attributable abbvie asset abbvie combine financial statement income tax expense defer tax balance calculate separate tax return basis abbvie operation historically include tax return file respective abbott entities abbvie business future stand entity abbvie file tax return behalf defer taxis effective tax rate differ historical period abbvie maintain income taxis payable tofrom account abbott exception certain entity outside united states transfer abbvie separation abbvie deem settle current tax balance abbott tax pay entity respective jurisdiction settlement reflect change net parent company investment cash equivalent cash equivalent include time deposit money market fund original maturity month investment shortterm investment consist primarily time deposit treasury security carry fair value investment marketable equity security classify availableforsale record fair value unrealize holding gain loss net tax include accumulate comprehensive income loss investment equity security trade public stock exchange heldtomaturity debt security record cost abbvie review carry value investment quarter determine temporary decline market value exist abbvie consider factor affect investee factor affect industry investee operate general equity market trend company consider length time investment market value cost nearterm prospect recovery abbvie determine temporary decline occur cost basis investment write charge income availableforsale security unrealized loss recognize charge income remove accumulate comprehensive income loss aoci account receivable account receivable state net realizable value allowance gross account receivable reflect good estimate probable loss inherent receivables portfolio determine basis historical experience specific allowance know troubled account currently available information account receivable write reasonable mean collect include litigation appropriate exhausted allowance million december million december inventory inventory value low cost firstin firstout basis market cost include material conversion cost inventory net consist follow december million finish good workinprocess material inventory net property equipment december million land building equipment construction progress property equipment gross accumulate depreciation property equipment net depreciation property equipment record straightline basis estimate useful life asset estimate useful life building range year average depreciation period year year equipment average depreciation period year leasehold improvement amortize life relate facility lease include renewal period appropriate asset whichever short depreciation expense year end december million million million respectively equipment include certain computer software software development cost incur connection develop obtain software internal use asset capital lease include property equipment combine balance sheet material litigation loss contingency provision record probable loss management good estimate loss good estimate minimum loss contingency record legal fee expense incur product liability abbvie accrue product liability claim undiscounte basis probable liability incur liability reasonably estimate base exist information liability adjust quarterly additional information available receivables insurance recovery product liability claim record asset undiscounte basis probable recovery realize business combination result operation acquire company include abbvie result operation respective acquisition date asset acquire liability assume recognize date acquisition respective fair value excess purchase price estimate fair value net asset acquire recognize goodwill contingent consideration recognize estimate fair value acquisition date determine utilize probability weight discount cash flow model subsequent change fair value contingent payment recognize earning allocation purchase price certain case subject revision base final determination fair value legal cost audit fee business valuation cost business acquisition cost expense incur goodwill intangible asset purchase intangible asset record fair value discount cash flow model discount cash flow model require assumption time future net cash flow risk cost capital terminal value market participant definitelive intangible amortize estimate useful life abbvie review recoverability definitelive intangible asset event change circumstance indicate carry value asset recoverable impairment review compare project undiscounted cash flow generate asset carrying value undiscounte cash flow intangible asset carrying value intangible asset intangible asset write fair value usually discount cash flow loss record equal excess asset net carrying value fair value cash flow identify individual asset review apply low level cash flow identifiable goodwill indefinitelive asset amortize subject impairment review annually indicator impairment exist impairment goodwill occur carry reporting unit exceed fair value reporting unit calculate weight income approach market approach fair value income approach calculate present value estimate cash flow discount riskfree market rate adjust market participant view similar company perceive risk cash flow fair value market approach calculate market multiple peer group apply operating result report unit determine fair value imply fair value goodwill determine subtract fair value identifiable net asset goodwill fair value reporting unit impairment charge record excess carrying goodwill imply fair value base company recent annual impairment test perform quarter fair value report unit substantially excess carrying value indefinitelive asset test impairment compare fair value intangible asset carrying value value indefinitelive base present value project cash flow income approach carry value exceed fair value intangible asset consider impaired reduce fair value acquire inprocess research development initial cost right acquire inprocess research development iprd project acquire asset acquisition expense iprd project alternative future use cost include initial payment incur prior regulatory approval connection research development collaboration agreement provide right develop manufacture market andor sell pharmaceutical product fair value iprd project acquire business combination capitalize account indefinitelive intangible asset underlie project receive regulatory approval point intangible asset account definitelive intangible asset discontinuation point intangible asset write development cost incur acquisition expense incur indefinite definitelive asset subject impairment review discuss previously foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize comprehensive income oci net asset subsidiary highly inflationary economy remeasure functional currency report currency remeasurement recognize earning immaterial year present derivative derivative instrument recognize asset liabilitie fair value combine balance sheet classify current longterm base schedule maturity instrument accounting change fair value derivative instrument depend formally designate qualify hedge relationship applicable accounting standard type hedging relationship derivative formally designate hedge company assess inception quarterly hedge derivative highly effective offset change fair value cash flow hedge item change fair value derivative designate fair value hedge hedge item attributable hedge risk recognize earning immediately fair value hedge hedge interest rate risk associate certain company fixedrate debt effective portion change fair value derivative designate cash flow hedge report aoci subsequently recognize earning consistent underlying hedged item cash flow hedge manage exposure change foreign currency exchange rate derivative designate qualify hedge adjust fair value current earning determine derivative long highly effective hedge company discontinue hedge account prospectively gain loss immediately reclassify aoci earning relate hedge forecast transaction long probable occur gain loss relate termination effective cash flow hedge forecast transaction probable occur defer recognize consistent income loss recognition underlie hedged item termination fair value hedge result cumulative fair value adjustment hedge item date termination amortize earning remain term hedge item derivative include designate hedge principally classified operating section combine statement cash flow consistent underlying hedged item refer note information abbvie derivative hedging activity earning share numerator basic diluted earning common share ep net earning attributable abbvie denominator basic diluted eps base number share abbvie common stock outstanding distribution date january distribution date abbott shareholders record close business december receive share abbvie common stock share abbott common stock hold record date basic diluted earning common share average number common share outstanding calculate number abbvie common share outstanding immediately follow distribution number share calculate basic diluted earning share abbvie equity award outstanding prior distribution year end december millions share amount net earning basic diluted earning common share basic diluted average share outstanding note supplemental financial information interest expense net year end december million interest dividend income interest expense interest expense net income expense income expense net include income million resolution contractual agreement loss million impairment equity security income expense net include loss million million fair value adjustment accretion contingent consideration relate acquisition solvay pharmaceuticals business solvay income expense net include ongoing contractual payment takeda associate conclusion tap pharmaceutical products inc joint venture account payable accrue liability december million sale rebate account payable salary wage commission royalty license arrangement government investigation acquire iprd account payable accrue liability longterm liability december millions defer income taxis pension postemployment benefit longterm liability accumulate comprehensive income loss netoftax component aoci component parent company equity follow december millions bracket denote loss cumulative foreign currency translation gain adjustment pension postemployment benefit cumulative unrealized gain marketable equity security cumulative lossesgain derivative instrument designate cash flow hedge accumulate comprehensive loss note acquisition collaboration arrangement cash outflow related acquisition collaboration arrangement total million million billion respectively abbvie record iprd charge million million million respectively follow significant acquisition investment include license collaboration agreement require contingent milestone payment acquisition solvay pharmaceuticals february abbvie acquire solvay certain product right approximately billion cash plus contingent payment eur million year certain sale milestone meet total consideration value billion include billion cash payment plus estimate fair value milestonebase contingent payment approximately million estimate fair value contingent consideration base estimate probability achieve specify sale milestone discount base expect time payment subsequent change fair value contingent payment recognize earning transaction provide abbvie complementary pharmaceutical product portfolio include right androgel creon worldwide right duodopa research development project abbvie acquire control business february financial result acquire operation include financial statement begin date net sale acquire operation approximately billion solvay acquisition take place january combine net sale net earning significantly different report amount acquisition fund cash shortterm investment allocation fair value arrangement acquisition date show table billion acquire intangible asset nondeductible iprd nondeductible goodwill nondeductible deferred income taxis total consideration excess purchase price fair value asset acquire liability assume approximately million record goodwill goodwill attributable expect synergies benefits abbvie believe result acquisition acquire intangible asset consist primarily product right currently market product amortize year average year acquire iprd project account indefinitelive intangible asset regulatory approval discontinuation facet biotech corporation april abbvie acquire outstanding share facet biotech corporation facet approximately million cash net cash hold facet acquisition enhance abbvie earlyand midstage pharmaceutical pipeline include daclizumab biologic multiple sclerosis oncology compound substantial portion fair value acquisition include million daclizumab allocate acquire iprd project account indefinitelive intangible asset regulatory approval discontinuation facet acquisition take place january combine net sale net earning significantly different report amount collaboration arrangement company enter collaborative agreement party develop commercialize drug candidate collaborative activity include joint research development commercialization new product abbvie generally receive certain licensing right arrangement collaboration require upfront payment include additional milestone research development cost share royalty profit share payment contingent occurrence certain future event link success asset development commercialization upfront payment associate collaborative arrangement development stage expense iprd subsequent payment partner achievement milestone development stage expense milestone achieve milestone payment partner subsequent regulatory approval capitalize intangible asset amortize cost product sell estimated useful life relate asset royalty salesbase milestone expense cost product sell incur reata pharmaceuticals inc abbvie enter series transaction reata pharmaceuticals inc reata abbvie acquire equity interest reata million abbvie enter agreement acquire licensing right outside united states exclude certain asian market bardoxolone methyl product development treatment chronic kidney disease result charge iprd million achievement certain development milestone license agreement result charge million million iprd additional payment million require achievement certain development regulatory milestone associate chronic kidney disease compound development fourth quarter abbvie enter collaboration reata joint development commercialization secondgeneration oral antioxidant inflammation modulator result charge iprd million pay quarter october reata informed abbvie discontinuing phase iii clinical study bardoxolone methyl chronic kidney disease reata abbvie closely examine datum study determine appropriate path forward development bardoxolone methyl chronic kidney disease indication fourth quarter abbvie record charge million income expense net impairment equity investment reata seattle genetics inc october abbvie record charge iprd million result enter twoyear collaboration agreement seattle genetics inc research develop commercialize compound antibodydrug conjugate approach additional payment million license compound require base achievement specify development regulatory commercial milestone agreement action pharma abbvie record charge iprd million result acquisition abt previously refer drug development prevention acute kidney injury associate major cardiac surgery patient increase risk galapagos february abbvie record charge iprd million result enter global collaboration galapagos develop commercialize nextgeneration oral janus kinase jak inhibitor phase development potential treat multiple autoimmune disease additional payment approximately billion require achievement certain development regulatory commercial milestone agreement biotest june abbvie enter global agreement biotest develop commercialize anitcd treatment rheumatoid arthritis psoriasis result million charge iprd abbvie future require additional payment total million base achievement certain development regulatory commercial milestone agreement neurocrine biosciences inc june abbvie enter exclusive worldwide agreement neurocrine biosciences inc develop commercialize product treatment endometriosis result million charge iprd abbvie future require additional payment million base achievement certain development regulatory commercial milestone agreement note goodwill intangible asset carry goodwill december million million respectively change goodwill balance foreign currency translation december accumulate goodwill impairment loss follow table summarize abbvie intangible asset december december gross net gross net carry accumulate carrying carry accumulate carry million amortization amortization definitelive intangible asset develop product right license agreement total definitelive intangible asset indefinitelive research development total intangible asset indefinitelive intangible asset relate iprd acquire business combination amortization expense million million million respectively abbvie record impairment charge million million respectively certain project development charge include expense december anticipate annual amortization expense intangible asset record december million million million million million intangible asset amortization include cost product sell combined statement earning amortizable intangible asset amortize year average year develop product right license agreement note restructure plan prior year abbvie management approve plan realign worldwide manufacturing operation select domestic international commercial operation order reduce cost abbvie record charge approximately million employee severance contractual obligation primarily relate exit facility million classify million sga expense abbvie record charge million reflect employee severance relate charge million classify cost product sell million million sga expense follow summarize activity restructuring millions accrue balance december payment adjustment accrue balance december restructuring charge payment adjustment accrue balance december restructuring charge payment adjustment accrue balance december additional million million million subsequently record respectively relate restructuring primarily accelerate depreciation solvay plan abbvie management approve restructuring plan primarily relate acquisition solvay plan streamline operation improve efficiency reduce cost certain solvay site function certain abbvie solvay commercial organization country abbvie record charge million million classify cost product sell million classify million classify sga expense follow summarize employee severance activity restructure million employee severance charge payment adjustment accrue balance december payment adjustment accrue balance december payment adjustment accrue balance december additional million million record respectively relate restructuring primarily accelerate depreciation asset impairment note debt credit facility commitment contingency longterm debt follow summary longterm debt december effective interest rate millions float rate note note note note note note fair value hedge unamortized bond discount total longterm debt lease obligation current portion noncurrent portion exclude effect related interest rate swap november abbvie issue billion aggregate principal senior note approximately billion senior note issue abbott partial consideration transfer asset abbott abbvie abbvie net proceed sale senior note senior note issue abbott finance payment november billion distribution abbott provide term separation agreement debt guarantee abbott abbvie separate abbott january abbvie redeem senior note series float note time senior note series float note time time redemption price equal principal senior note redeem plus makewhole premium abbvie redeem float note prior maturity debt issuance cost incur connection senior note debt offering total million amortize respective term note interest expense combine statement earning december company compliance senior note covenant shortterm borrowing december shortterm borrowing include billion commercial paper borrowing weightedaverage interest rate shortterm borrowing december abbvie billion unsecured bank credit facility agreement back commercial paper program mature july abbott relieved obligation credit facility separation abbvie abbott january abbvie sole obligor facility credit facility enable company borrow fund unsecured basis float interest rate december company compliance credit facility covenant compensate balance commitment fee material lease separation abbvie enter agreement lease certain facility include office laboratory factory warehouse space principally noncancelable operating lease lease generally provide company pay taxis maintenance insurance operating cost lease property abbvie lease office space shortterm basis typically cancelable operating lease company capital lease obligation principally automobile december annual future minimum lease payment material future minimum lease payment longterm debt maturity year end december million later year total obligation commitment fair value hedge unamortized bond discount current longterm debt lease obligation contingency guarantee connection distribution abbvie indemnify abbott liability result operation abbvie business income tax liability respect period prior distribution date liability agree abbvie abbott abbvie material exposure offbalance sheet arrangement specialpurpose entity activity include nonexchangetrade contract account fair value ordinary course business abbvie periodically enter thirdparty agreement assignment product right result abbvie secondarily liable obligation abbvie previously primarily liable abbvie long maintain business relationship party abbvie unable develop estimate maximum potential future payment obligation base past experience likelihood payment agreement remote abbvie periodically acquire business product right abbvie agree pay contingent consideration base attain certain threshold base occurrence certain event note financial instrument fair value measure risk management policy company expose foreign currency exchange rate interest rate risk relate business operation company hedge policy attempt manage risk acceptable level base company judgment appropriate tradeoff risk opportunity cost company use derivative instrument reduce exposure foreign currency exchange rate company expose risk earning cash flow adversely impact fluctuation interest rate company periodically enter interest rate swap base judgment manage interest cost company agree exchange specify interval difference fix float interest amount calculate reference agreedupon notional derivative instrument trading purpose manage exposure change interest rate investment security company outstanding derivative instrument contain credit risk relate contingent feature financial instrument abbvie foreign subsidiary enter foreign currency forward exchange contract manage exposure change foreign exchange rate anticipate intercompany transaction denominate currency functional currency local entity contract total billion million december respectively designate cash flow hedge record fair value accumulate gain loss december include cost product sell time product sell generally month company enter foreign currency forward exchange contract manage exposure foreign currency denominate trade payable receivables intercompany loan contract markedtomarket result gain loss reflect income generally offset loss gain foreign currency exposure manage december abbvie hold billion billion respectively foreign currency forward exchange contract abbvie party interest rate hedge contract designate fair value hedge total billion december effect hedge change fixedrate interest obligation float rate portion debt abbvie record contract fair value adjust carrying fix rate debt offset follow table summarize amount location abbvie derivative instrument december fair valueasset fair valueliabilitie million balance sheet caption balance sheet caption interest rate swap designate fair value hedge longterm liability foreign currency forward exchange contract prepay expense account payable accrue hedging instrument liability prepaid expense account payable accrue designate hedge liability total follow table summarize activity derivative instrument amount location income expense gain loss reclassify income certain derivative instrument year end december hedge ineffectiveness significant loss gain recognize income expense gain loss comprehensive reclassify loss income income million income statement caption foreign currency forward exchange contract designate cash flow hedge cost product sell net foreign exchange gain designate hedge loss interest rate swap designate fair value hedge interest expense net loss million relate fair value hedge recognize net interest expense offset equally million gain underlie hedged item fixedrate debt fair value measure fair value hierarchy accounting standard fair value measurement consist follow level level valuation base unadjusted quote price active market identical asset company ability access level valuation base quote price similar instrument active market quote price identical similar instrument market active modelbase valuation significant input observable market level valuation significant input unobservable market include use judgment company management assumption market participant use price asset liability follow table summarize basis measure certain asset liability carry fair value recur basis combine balance sheet december basis fair value measurement quote price active significant market significant balance identical observable unobservable december asset input input million level level level asset cash equivalent certificate deposit treasury securities equity security foreign currency forward contract total asset liabilitie interest rate hedge foreign currency forward contract contingent consideration total liability basis fair value measurement quote price active significant market significant balance identical observable unobservable december asset input input million level level level asset cash equivalent treasury securities equity security foreign currency forward contract total asset liability foreign currency forward contract contingent consideration total liability availableforsale equity security consist investment fair value determine publish market price unit multiply number unit hold consideration transaction cost derivative enter company value publicize spot forward price foreign currency hedge publicize swap curve interest rate hedge contingent payment value discount cash flow technique reflect management expectation probability payment gross unrealized holding gain availableforsale equity security total million million december respectively transfer asset liability fair value measurement level follow table reconciliation fair value measurement use significant unobservable input level consist contingent payment relate acquisition million fair value december loss recognize earning fair value december payment loss recognize earning fair value december connection acquisition solvay pharmaceuticals business achievement certain sale milestone result payment approximately million liability previously establish addition financial instrument company require recognize fair value combine balance sheet company certain financial instrument recognize historical cost basis fair value carry value fair value certain financial instrument december show table approximate book value fair value million asset investment liability shortterm borrowing current maturity longterm debt lease obligation longterm debt lease obligation follow table summarize basis measure approximate fair value financial instrument december basis fair value measurement quote price active significant market significant fair value identical observable unobservable december asset input input million level level level asset investment total asset liability shortterm borrowing current maturity longterm debt lease obligation longterm debt lease obligation total liability investment consist cost method investment heldtomaturity debt security determine fair value cost method investment company take consideration recent transaction financial information investee represent level basis fair value measurement fair value heldtomaturity debt security longterm debt estimate base quote market price similar debt instrument fair value shortterm current borrowing approximate carry value short maturity instrument material adjustment fair value year end december asset liability measure fair value recur basis discuss note impairment company investment reata counterpartie financial instrument consist select major international financial institution concentration risk company invest excess cash time deposit money market fund treasury security diversifie concentration cash different financial institution company monitor concentration credit risk associate deposit financial institution credit exposure limit establish limit concentration single issuer institution wholesaler account percent percent total net account receivables december respectively substantially abbvie sale wholesaler addition governmental account greece portugal italy spain account percent percent total net account receivable december respectively note postemployment benefit abbott sponsor plan abbvie employee participate certain international define benefit pension postemployment plan sponsor abbott plan include participant abbott business account multiemployer plan abbvie combine financial statement result asset liability record abbvie historical balance sheet december recognize fund status plan abbott voluntary contribution define benefit pension fund abbvie account multiemployer plan total million million million respectively multiemployer pension plan approximately percent percent fund december respectively connection separation abbvie abbott january plans separate abbott transfer certain liability asset plans abbvie estimate amount assume abbvie show table define postemployment million benefit plan plan accumulate benefit obligation defer loss project benefit obligation fair value asset net liability abbott sponsor define benefit postemployment benefit plan abbvie record expense million million abbvie sponsor plan abbvie sole sponsor certain define benefit pension postemployment plan reflect combined balance sheet december preparation separation abbott certain pension postemployment benefit plan assume abbvie reflect december combine balance sheet abbvie voluntary contribution abbvie sponsor pension plan million million million respectively quarter abbvie voluntary contribution million main domestic define benefit pension plan assume benefit plan information table pertain abbvie sponsor pension postemployment plan define postemployment benefit plan plan year end december millions project benefit obligation begin period service cost interest cost assumption plan liabilitie actuarial loss gain benefit pay primarily foreign currency translation loss gain end period fair value plan asset begin period actual return plan asset company contribution assumption plan asset benefit pay end period fund status december amount recognize combined balance sheet asset current liability longterm liability net liability december actuarial loss net prior service cost aoci december project benefit obligation pbo table include billion million december respectively relate international define benefit pension plan generally fund accordance local regulation benefit payment plan fund company asset plan reflect table accumulate benefit obligation abo billion million december respectively plan reflect table abo exceed plan asset december abo pbo aggregate plan asset million billion million respectively amount recognize aoci oci pension postemployment plan gain loss prior service cost credit recognize net periodic benefit cost recognize netoftax basis aoci amortize net periodic benefit cost future follow summary pretax loss include oci millions actuarial loss prior service cost amortization prior service cost actuarial loss foreign exchange loss total pretax loss recognize oci december actuarial loss amortization prior service cost actuarial loss foreign exchange loss total pretax loss recognize oci december pretax actuarial loss prior service cost include aoci december expect recognize net periodic benefit cost million define benefit plan million postemployment plan net periodic benefit cost year end december million service cost interest cost expect return plan asset amortization actuarial loss prior service cost net periodic pension benefit cost weightedaverage assumption determine benefit obligation measurement date discount rate rate compensation increase assumption calculate december measurement date benefit obligation calculation net periodic benefit cost weightedaverage assumption determine net periodic benefit cost discount rate expect longterm rate return plan asset expect rate change compensation pension plan asset basis fair value measurement quote price significant significant balance active market observable unobservable december identical asset input input million level level level equitie large capa mid capb internationalc fix income security government securitiesd corporate debt instrumentse government security international absolute return fundsf real asset otherg fair value plan asset basis fair value measurement quote price significant significant balance active market observable unobservable december identical asset input input million level level level equitie large capa mid capb internationalc fix income security government securitiesd corporate debt instrumentse absolute return fundsf otherg fair value plan asset mix index fund track percent percent separate actively manage equity account benchmarke russell percent percent mix index fund percent separate actively manage equity account percent track benchmarke midcap index primarily separate actively manage pooled investment account benchmarke msci emerge market local index index fund percent percent separate actively manage account percent percent index fund percent percent separate actively manage account percent percent primarily fund invest manager global mandate flexibility allocate capital broadly wide range asset class strategy include limited equity fix income commodity interest rate future currency security outperform agree benchmark specific return volatility target primarily investment liquid commodity future contract private energy fund cash cash equivalent equity value quote price value publish market price equitie common collective trust register investment company value significant observable input value net asset value nav provide fund administrator nav base value underlie asset own fund minus liability fix income security value significant observable input value price obtain independent financial service industryrecognize vendor absolute return fund commodity value nav provide fund administrator follow table summarize change value plan asset measure significant unobservable input level million january transfer category actual return plan asset hand year end purchase sale settlement net december investment mix equity security fix income asset allocation strategy base achieve desire return balance high return volatile equity security low return volatile fix income security investment allocation range market industry sector capitalization size case fix income security maturity credit quality know significant concentration risk plan asset plan expect return asset show base management expectation longterm average rate return achieve underlie investment portfolio establish assumption management consider historical expect return asset class plan invest current economic capital market condition expect pension postemployment payment define postemployment million benefit plan plan table reflect total benefit payment expect pay participant include payment fund company asset pay plan abbvie employee participate abbott laboratories stock retirement plan abbott principal define contribution plan abbvie record expense million million million year end december respectively relate plan abbvie provide certain postemployment benefit primarily salary continuation plan qualify employee accrue related cost service live employee note stockbase compensation prior separation abbvie employee participate abbott incentive stock program conjunction separation company adopt abbvie incentive stock program provide assumption certain award grant abbott incentive stock program authorize grant different form benefit include nonqualified stock option restrict stock award rsas restrict stock unit rsus abbvie incentive stock program initially reserve million share common stock issuance respect award participant subsequent yearend reserve reduce approximately million share stock option rsa rsu award grant abbvie board director follow disclosure represent portion abbott incentive stock program abbvie employee participate award grant program consist abbott common share relate equity account balance reflect abbott consolidated statement stockholder equity reflect abbvie combine financial statement abbvie combine statement earning reflect compensation expense stockbase awards associate portion abbott incentive stock program abbvie employee participate accordingly amount present necessarily indicative future performance necessarily reflect result abbvie experience independent publiclytraded company period present equity award amount present convert reflect separation abbott separation january holders abbott stock option rsas rsus generally receive abbvie stockbased award abbott stockbased award outstanding value combine abbott abbvie stockbased award separation design generally preserve intrinsic value fair value award immediately prior separation share datum present note adjust reflect impact separation stock compensation expense stock compensation expense recognize combined statement earning million million million respectively relate tax benefit recognize million million million respectively half stockcompensation expense classify sga remainder classify cost product sell compensation cost capitalize combined balance sheet december significant compensation expense stockbase award measure base fair value award date sharebase award grant adjust estimate number award expect vest forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate compensation cost stockbase award amortize service period shorter vest period employee retirement eligible charge compensation expense stockbase award grant retirementeligible employee compensation expense recognize immediately grant date employee able retain award continue provide service stock option exercise price option grant equal percent market value date grant stock option typically contractual term year generally vest onethird increment threeyear period option replacement feature pre option grant replacement option feature term condition replacement option material respect applicable original grant exercise price option replacement option feature pay common share hold employee replacement option grant number share payment closing price common share business day exercise determine number share require exercise relate option exercise price replacement option replacement option exercisable month date grant term expire expiration date original option fair value stock option determine blackschole model weightedaverage assumption estimate fair value stock option grant year weightedaverage grantdate fair value follow year end december riskfree interest rate average life option year volatility dividend yield fair value stock option riskfree interest rate base rate available time grant zerocoupon government issue remain term equal option expect life average life option base historical project exercise lapse datum expect volatility base imply volatility trade option abbott stock historical volatility abbott stock expect life option dividend yield base option exercise price annual dividend rate time grant follow table summarize stock option activity year end december stock option outstanding balance december abbott incentive stock program abbvie employee weight weighted option thousand aggregate intrinsic average average remain aggregate value million option exercise price life year intrinsic value outstanding december grant exercise lapsed outstanding december exercisable december aggregate intrinsic value table represent difference exercise price closing stock price day trading year total intrinsic value option exercise million million million respectively december million unrecognized compensation cost relate stock option expect recognize expense year rsas rsus restrict stock award generally vest year restrict stock award vest year onethird award vest year rsus vest year vest recipient receive share common stock vest restricted stock unit fair value rsas rsus determine base number share grant quote price common stock date grant follow table summarize rsas rsus balance activity abbott incentive stock program abbvie employee weight average share unit thousand share unit grant date fair value nonveste share december grant vested lapsed nonveste share december fair market value restrict stock award unit vest million million million respectively december million unrecognized compensation cost relate rsas rsus expect recognize expense year note income taxis earning income taxis year end december million domestic foreign total earning income taxis income taxis year end december million current domestic foreign total current taxis defer domestic foreign total defer taxis total income taxis effective tax rate reconciliation year end december million statutory tax rate benefit low tax rate tax exemption primarily puerto rico resolution certain tax position pertain prior year effect nondeductible litigation loss accrual puerto rico excise tax credit state taxis net federal benefit net effective tax rate income taxis include recognition tax benefit total approximately million million respectively result favorable resolution tax position pertain prior year income taxis reflect nondeductibility litigation reserve exclude discrete item effective tax rate statutory federal income tax rate percent principally benefit low statutory tax rate tax exemptions puerto rico foreign tax jurisdiction reduce tax rate percentage point respectively puerto rico enact legislation assess excise tax begin certain product manufacture puerto rico tax levy gross inventory purchase entities puerto rico include cost product sell combined statement earning majority tax creditable income tax purpose excise tax total approximately million million respectively december income taxis provide approximately billion undistributed foreign earning earning indefinitely reinveste continued use foreign operation practicable determine defer income taxis provide earning defer tax asset liability december millions defer tax asset compensation employee benefit trade receivable reserve inventory reserve defer intercompany profit state income taxis total defer tax asset defer tax liability depreciation primarily excess book basis tax basis intangible asset total defer tax liability net defer tax asset unrecognized tax benefit year end december millions january increase current year tax position increase prior year tax position decrease current year tax position decrease prior year tax position settlement december abbvie abbott enter tax sharing agreement effective date separation tax contingency prior separation abbott indemnify hold abbvie harmless tax position settle amount excess record liability abbvie benefit prior tax position resolve favorably record amount result liability uncertain tax position record combine financial statement december note litigation number patent dispute party claim abbvie product infringe patent february supreme court deny centocor inc new york university petition review february federal circuit court appeal decision reverse billion judgment favor centocor new york university patent claim abbvie humira infringe decision conclude case department justice attorney western district virginia state attorney general investigate abbvie sale marketing activity depakote government seek determine activity violate civil andor criminal law include federal false claim act food drug cosmetic act antikickback statute connection medicare andor medicaid reimbursement party state attorney general office seek determine activity violate state law include state consumer fraudprotection statute abbvie record charge billion quarter million quarter relate civil criminal claim arise matter abbvie reach resolution depakoterelate federal claim medicaidrelate claim state district columbia consumer protection claim state district columbia abbvie pay approximately billion settlement payment material abbvie cash flow record accrual balance litigation december significant year legal proceeding occur result change estimate loss accrue abbvie feasible predict outcome proceeding exposure certainty management believe ultimate disposition material adverse effect abbvie financial position cash flow result operation note related party transaction abbott historical financial statement abbott provide abbvie certain service include administration treasury payroll employee compensation benefit travel meeting service public investor relation real estate service internal audit telecommunication information technology corporate income tax select legal service service provide abbvie temporary basis separation financial information combine financial statement necessarily include expense incur abbvie separate standalone entity financial information necessarily reflect combine financial position result operation cash flow abbvie future abbvie separate standalone entity period present management believe method allocate expense abbvie reasonable allocation method include relative sale headcount square footage number transaction measure allocation total million million million year end december respectively abbvie incur million separationrelate expense include legal information technology regulatory fee principally classify sga december outstanding intercompany transaction abbvie abbott reflect abbott laboratories abbott laboratory combine balance sheet note segment geographic area information abbvie operate business segmentpharmaceutical product substantially abbvie sale wholesaler outside united states product sell primarily health care provider distributor depend market serve net sale key product follow year end december millions humira androgel tricortrilipix kaletra niaspan synagis lupron sevoflurane synthroid norvir zemplar creon net sale net sale external customer base country sell product follow year end december millions united states netherlands germany japan united kingdom spain france canada brazil italy country net sale longlive asset consist net property equipment united states puerto rico total approximately billion billion december respectively note quarterly financial datum unaudite million share datum quarter net sale gross margin net earning basic diluted earning share second quarter net sale gross margin net earning basic diluted earning share quarter net sale gross margin net earning basic diluted earning share fourth quarter net sale gross margin net earning basic diluted earning share computation basic diluted earning share period calculate share distribute january report independent register public accounting firm board director shareholders abbvie inc audit accompany combine balance sheet abbvie inc subsidiary company december relate combined statement earning comprehensive income statement parent company equity cash flow year period end december combine financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance auditing standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance combine financial statement free material misstatement company require engage perform audit internal control financial reporting audits include consideration internal control financial reporting basis design audit procedure appropriate circumstance purpose express opinion effectiveness company internal control financial reporting accordingly express opinion audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion combine financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america describe note accompany combine financial statement derive consolidated financial statement accounting record abbott laboratory combine financial statement include expense allocation certain corporate function historically provide abbott laboratory allocation reflective actual expense incur company operate separate legal entity apart abbott laboratories deloitte touche llp chicago illinois march item change disagreement accountant account financial disclosure previously report abbvie current report form date december audit committee abbvie board director approve dismissal deloitte touche llp deloitte abbvie independent register public accountant effective date deloitte completion audit service fiscal year end december filing abbvie annual report security exchange commission approve appointment ernst young llp abbvie independent register public accounting firm perform independent audit service begin fiscal year end december fiscal year end december march disagreement term define item aiv regulation relate instruction abbvie deloitte matter accounting principle practice financial statement disclosure auditing scope procedure resolve satisfaction deloitte caused deloitte reference subject matter disagreement connection report abbvie combine financial statement year reportable event term define item regulation item control procedure disclosure control procedure evaluation disclosure control procedure chief executive officer richard gonzalez chief financial officer william chase evaluate effectiveness abbvie disclosure control procedure end period cover report conclude abbvie disclosure control procedure effective ensure information abbvie require disclose report file submit securities exchange commission securities exchange act record process summarize report time period specify commission rule form ensure information require disclose abbvie report file submit exchange act accumulate communicate abbvie management include principal executive officer principal financial officer appropriate allow timely decision require disclosure internal control financial reporting management annual report internal control financial reporting annual report include report management assessment internal control financial reporting attestation report company register public accounting firm transition period establish rule sec newly public company change internal control financial reporting quarter end december change abbvie internal control financial reporting define rule exchange act materially affect reasonably likely materially affect abbvie internal control financial report inherent limitation effectiveness control abbvie management include chief executive officer chief financial officer expect abbvie disclosure control internal control financial reporting prevent detect error fraud control system matter design operate provide reasonable absolute assurance control system objective meet design control system reflect fact resource constraint benefit control consider relative cost inherent limitation control system evaluation control provide absolute assurance misstatement error fraud occur control issue instance fraud detect inherent limitation include reality judgment decisionmake faulty breakdown occur simple error mistake control circumvent individual act person collusion people management override control design system control base certain assumption likelihood future event assurance design succeed achieve state goal potential future condition projection evaluation control effectiveness future period subject risk time control inadequate change condition deterioration degree compliance policy procedure item information iii item director executive officer corporate governance incorporate reference information concern director nominee board director committeescommittee board director section beneficial ownership report compliance procedure recommendation nomination director transaction business annual meeting include abbvie inc proxy statement proxy statement file march incorporate reference text find caption executive officer registrant page hereof abbvie code business conduct require business activity conduct compliance law regulation ethical principle value director officer employee abbvie require read understand abide requirement code business conduct applicable waiver code business conduct director executive officer abbvie audit committee abbvie disclose amendment waiver provision code conduct principal executive officer principal financial officer principal accounting officer controller person perform similar function website business day follow date amendment waiver addition abbvie disclose waiver code business conduct executive officer director website abbvie chief ethic compliance officer report chief executive officer public policy committee chief ethic compliance officer responsible overseeing administer monitor abbvie compliance program item executive compensation material include proxy statement heading director compensation executive compensation compensation committee report incorporate reference proxy statement file march item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information abbvie outstanding share issue company equity compensation plan december information concern security ownership incorporate reference material head ownership securitiessecurity ownership executive officer director proxy statement proxy statement file march item certain relationship relate transaction director independence material include proxy statement heading board director committee corporate governance material procedure approval related person transaction transaction abbott incorporate reference proxy statement file march item principal accounting fee service material include proxy statement heading audit informationaudit fee nonaudit fee audit information policy audit committee preapproval audit permissible nonaudit services independent auditor incorporate reference proxy statement file march item